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 Abstract 
Catechins are the major polyphenolic compound in green tea that have been investigated 
extensively over the past few decades in relation to the treatment of various chronic 
diseases including diabetes, cardiovascular disease, and cancer.  O-methylation is a major 
Phase II metabolic pathway of green tea catechins (GTCs) via the enzyme catechol-O-
methyltransferase (COMT). A single nucleotide polymorphism in the gene coding for 
COMT leads to individuals with a high-, intermediate-, or low-activity COMT enzyme.  
An epidemiological case-control study suggests that green tea consumption is associated 
with reduced risk of breast cancer in women with an intermediate- or low-activity COMT 
genotype.  A cross-sectional analysis discovered that men homozygous for the low-
activity COMT genotype showed a reduction in total tea polyphenols in spot urine 
samples compared to the intermediate- and high-activity genotypes.  Several human 
intervention trials have assessed green tea intake, metabolism, and COMT genotype with 
conflicting results.  The aim of the present study was to determine if the COMT 
polymorphism would modify the excretion and plasma levels of GTCs in 180 
postmenopausal women at high risk for breast cancer consuming a green tea extract 
supplement containing 1222 mg total catechins daily for 12 months.  All participants in 
the study were a sub-set from the larger parent study “Green Tea and Reduction of Breast 
Cancer Risk.”  Thirty subjects with the high-activity COMT genotype, thirty with 
intermediate-activity COMT genotype, and thirty with low-activity COMT genotype from 
each of the placebo and treatment groups were analyzed. No statistically significant 
differences were found in any urinary or plasma catechin metabolite measurements 
between the homozygous high-activity and homozygous low-activity COMT genotype in 
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 the treatment group.  Additionally, no differences were found when high-, intermediate-, 
and low-activity COMT genotypes were all compared in the treatment group.  This 
suggests that the COMT genotype does not play a major role in GTC metabolism. Dosing 
of GTC and timing of biological samples are important factors that may need further 
research in future trials evaluating the effect of COMT genotype and GTC metabolism.   
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 Introduction 
Tea is one of the most commonly consumed beverages in the world with over two-thirds 
of the world’s population drinking it. It is enjoyed for its good taste, attractive aroma, and 
health-promoting effects. Tea is a water infusion made from the dried leaves of Camellia 
sinensis originating in southern China.  The plant is now produced in several countries 
including China, India, Indonesia, Japan, Taiwan, Sri Lanka, and in countries of central 
Africa 1.  Over 300 different kinds of teas are presently manufactured from the dried plant 
leaf, but there are only three general categories of tea.  They include the unfermented 
green tea, the partially fermented oolong or pouchong tea, and the fermented black tea 2.  
Black tea is 78% of the total world tea produced and consumed mostly in the US and 
Europe.  Only 2% of world production consists of oolong tea, while green tea makes up 
20% of production and is prevalent in Japan and China 3. 
Green tea has been studied extensively for its health benefits.  Many of the beneficial 
properties surrounding green tea are associated with a compound called catechins in the 
tea leaves.  Green tea and its catechins have been investigated for its reduction of body 
weight, protection against diabetes, and prevention of cardiovascular disease and      
cancer 4.  The biotransformation of green tea catechins (GTC) are extensive causing the 
understanding of the role green tea plays in the prevention of disease to be complex 5.  
Different genetic variations in the enzymes that metabolize GTC may play a crucial role 
in the function green tea has in disease inhibition between individuals.  Some research 
studies have looked at this genetic variation 6, but more research is needed to give a clear 
picture of how green tea metabolism may affect disease prevention.   
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 Major Tea Components 
Fresh tea leaves have a high content of flavonoids.  Flavonoids are a diverse group of 
polyphenolic compounds that can be divided into several classes.  Two of these classes, 
flavanols and flavonols, are the predominate types of flavonoids found in tea.  Catechins, 
a flavan-3-ol, are the most abundant class of flavonoids in tea accounting for 30-42% of 
the dry weight of tea.  Flavonols and flavonol glycosides make up only 3% of the dry 
weight of tea.  These include quercetin, myricitin, kaempferol, and their glycosides.  
Roughly 2.5 to 4.0% of the dry weight of tea leaves contains caffeine and very small 
quantities of theobromine.  Phenolic acids and depsides make up 5% of the dry weight of 
tea.  The ash portion of the water-soluble extract solids of tea contains potassium, 
calcium, magnesium, and aluminum.  The tea beverage also contains about 1 mg of 
fluoride per serving.  Approximately 15 to 20% of the dry weight of tea is nitrogenous 
material.  Enzymes compose a large fraction of this, roughly 6% of the weight is amino 
acids, and 1% of the weight is nucleic acids.  There are 19 amino acids found in tea, and 
theanine is an amino acid unique to the beverage.  Carbohydrates make up about 5 to 7% 
of the dry weight consisting of cellulose, pectin, glucose, fructose, and sucrose 7,8.  
Fresh tea leaves are steamed or dried to prevent the enzymatic oxidation of catechins in 
the manufacturing of green tea.  When tea leaves are fermented to manufacture oolong or 
black tea, the fresh leaves are allowed to wither and are crushed 9.  This process of 
fermentation is initiated by the oxidation of catechins to reactive quinones. This oxidative 
polymerization of the catechins is dependent on the enzyme polyphenol oxidase and will 
form compounds such as bisflavanols, theaflavins, thearubigins and other oligomers.  
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 These products of fermentation give oolong and black tea its orange-yellow to red-brown 
color and different flavors 2,7.  Catechins are reduced by roughly 85% throughout the 
manufacturing of black tea 7.  Figure 1 shows the tea extraction processes. 
 
 
 
 
Figure 1: Schematic of the tea extraction processes adapted from reference 9 
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 The composition of tea can fluctuate depending on the age of tea leaf, the species, season, 
climate, and horticultural practices.  For example, a study done by Yung-Sheng et al. 
showed that there was less overall catechins in manufactured green tea from young tea 
leaves versus old tea leaves.  The level of caffeine was higher in the young tea leaves.  
The researchers also showed that young green tea leaves varied in the amount of 
catechins they contained depending on where the tea leaf was removed from the tea   
plant 1.   
Green Tea Catechins (GTC) 
Green tea and the major polyphenolic compounds it contains, catechins, have been 
investigated extensively. The bitter and astringent taste of the unfermented green tea is 
related to the colorless, water-soluble catechins within it.  There are four main types of 
catechins found in fresh tea leaves including (-)-epicatechin (EC), (-)-epicatechin gallate 
(ECG), (-)-epigallocatechin (EGC), and (-)-epigallocatechin gallate (EGCG) (7).  The 
major catechins are shown in figure 2 10. Catechins are differentiated by the meta-5, 7-
dihydroxy substitution of the A ring and their di- or tri-hydroxyl group substitution of the 
B ring. The de novo biosynthesis of flavonoids like catechins are formed through 
condensation reactions of cinnamic acids and acetic acid.  The synthesis of the flavonoids 
in tea requires enzymes of the shikimate/arogenate pathway, and the 5-dehydroshikimate 
reductase is a key regulatory enzyme in the process 7.  
A typical cup of green tea contains 30-42% of catechins by dry weight. EGCG is the 
most abundant and widely studied catechin of green tea can account for 50% to 80% of 
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 the total catechins in green tea 6,7.  Table 1 compares the polyphenol content of green and 
black tea.  The tea brews are 1.25% water extracts (1.25 g of tea leaves per 100 ml of 
water) of green and black tea 11.  Catechins are found in other food sources as well as 
green tea.  (+)-Catechin and EC are more commonly found in foods like fruits.  Black 
grapes, apricots, strawberries, and beans have especially high levels of catechins.  
Apples, blackberries, black grapes, cherries, pears, raspberries, chocolate, and broad 
beans are all higher in EC 12.  The gallate and gallocatechins, including EGCG, are almost 
found exclusively in tea and particularly in green tea.  
Table 1: Polyphenol Content by Tea Type 11 
 
 
 
Tea Polyphenols Green Tea (µg/ml) 
Black Tea 
(µg/ml) 
Total polyphenols 1064 300 
EGCG 444 128 
EGC 411 42 
ECG 90 73 
EC 98 37 
Catechin 21 20 
Flavonols and flavonol 
glycosides 
101 95 
Total theaflavines 0 64 
Undefined polyphenols 589 1466 
Total tea polyphenols 1754 1925 
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Figure 2: Major green tea catechins 10 
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 Tea & Health Benefits 
Tea has been used as a medicinal drink in China since as early as 3000 B.C. and was 
written in the ancient Chinese pharmacopoeia during the Ming dynasty of the 16th   
century 1.  This long history of tea providing health benefits has led to the research of tea 
in more recent times.  It has now been studied for its protective effects against cancer, 
cardiovascular, and other diseases. The polyphenolic compounds in tea have mostly been 
ascribed to these health benefits 13.  The biological functions of tea polyphenols are 
numerous and continue to be investigated.   
Tea polyphenols are recognized for their antioxidant and antibacterial activity.  In 
general, the antibacterial activity decreases the more the tea is fermented 14.  Strong 
antioxidant properties have been seen in both green and black tea13.  A study by Chan et 
al. compared the role of non-polymeric phenolic and polymeric tannin constituents in tea 
and found that non-polymeric phenolic compounds were the major contributor to the 
antioxidant and antibacterial role in tea 15.   Green tea was shown to have higher 
antioxidant and antibacterial properties than black or herbal teas. 
The health benefits of consuming green tea for a large variety of disorders have been 
reported.  Many of the advantages regarding green tea are associated with its catechins, 
particularly the EGCG content.  In vitro and animal studies have suggested the 
underlying mechanisms of GTCs and their biological actions 16,17.  GTCs have shown 
promising potential to treat common diseases through their ability to inhibit specific 
enzymes, to scavenge free radicals, and to simulate hormones and neurotransmitters 6.   
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 Green Tea & Weight Loss 
There is evidence that suggests that GTCs may reduce body weight and Body Mass Index 
(BMI).  In vitro data indicates that GTCs, especially EGCG, have an anti-obesity effect 
through various mechanisms.  A couple of these mechanisms include an inhibition of 
adipocyte differentiation and proliferation 18 and a reduction in fat absorption 19.  Animal 
studies have shown promising evidence that green tea may suppress the accumulation of 
body fat.  In recent years, popular study designs yielding these results have induced 
obesity in the animal models with a high-fat diet and then followed with a period of green 
tea supplementation 20-22.  Bose et al. investigated EGCG on high-fat diet induced obese 
mice.  EGCG was supplemented to a treatment group for either 16 or 4 weeks compared 
to the control group.  The longer term of EGCG treatment attenuated the development of 
obesity and fatty liver.  Shorter EGCG supplementation of 4 weeks decreased mesenteric 
fat weight in the mice and lowered the blood glucose compared to the control group 20. 
Green tea contains caffeine, which can also lead to changes in anthropometric 
measurements by increasing energy expenditure.  This factor needs to be taken into 
consideration when assessing the ability GTCs have on altering body weight.   A recent 
meta-analysis analyzed 15 human trials noting if caffeine was either in the GTC or 
placebo supplement used in the trial 23.  The trials ranged from 8 to 24 weeks in length 
with 33 to 240 participants.  Six of the trials used a GTC supplement that contained 
caffeine and a placebo that contained equal amounts of caffeine 24-29.  Statistical pooling 
of the data from these trials showed that consuming GTCs with caffeine at a dose ranging 
from 583 to 714 mg per day had a statistically significant beneficial effect on body 
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 weight (-1.38 kg; 95% CI: -1.78, -1.06), BMI (-0.55; 95% CI: -0.65, -0.40), and waist 
circumference (-1.93 cm; 95% CI: -2.82, -1.04).  No change was noted in waist-to-hip 
ratio.  Six of the total trials in the meta-analysis used a GTC supplement dosage of 474 
mg per day that contained caffeine, but the placebo used did not have caffeine 30-35.  
Grouping the results from these studies together revealed that GTC ingestion 
significantly reduced body weight (-0.44 kg; 95% CI: -0.72, -0.15), but it did not have an 
effect on BMI, waist circumference, or waist-to hip ratio.  Lastly, a trial using a range of 
300 mg per day of GTC supplementation without any caffeine and a placebo without 
caffeine had no significant results for any anthropometric measurements 36.   The results 
from these studies could indicate that the caffeine contained in green tea may play a role 
in the effect green tea has on anthropometric measurements.  More studies will need to be 
done using green tea supplements at different doses without caffeine to discover the true 
effect of green tea alone. 
Green Tea & Diabetes 
Type 2 diabetes is a major concern within many countries.  One of the crucial factors 
leading to the onset of type 2 diabetes is impaired insulin sensitivity and glucose control.  
The underlying mechanisms in which GTCs may improve glucose control have been 
explored mainly through in vitro and animal based studies.  In vitro data suggest that 
GTCs could reduce glucose absorption through the inhibition of gastro-intestinal 
enzymes involved in nutrient digestion.  Kobayashi et al. showed that GTCs significantly 
inhibited the sodium-dependent glucose transporter and reduced glucose uptake from the 
intestines of rats 37.  Another study discovered the importance of the esterified functional 
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 group in EGCG.  This functional group can suppress the production of glucose from 
maltose by inhibiting the α-glucosidase enzyme 38.   Additionally, animal studies have 
shown that consuming GTCs leads to an increase in glucose uptake in the skeletal 
muscle.  However, there is a decrease in glucose uptake in the adipose tissue 39.  GTCs 
may be activating or suppressing the expression of transcription factors related to 
adipogenesis.   
Epidemiological studies have shown that green tea may decrease the risk for diabetes.  A 
large epidemiological study conducted in Japan followed a total of 17,413 participants 
with no history of type 2 diabetes for up to five years.  Subjects who habitually consumed 
greater than 6 cups of green tea per day had a decreased risk for diabetes with an odds 
ratio of 0.67 (CI: 0.47-0.94) compared with subjects who drank less than one cup of 
green tea per week 40.  
Human intervention studies have studied this topic in more detail.  One placebo-
controlled study with 22 healthy volunteers had a treatment group that consumed 1.5 g of 
green tea powder containing 84 mg EGCG.  Consumption of the green tea powder prior 
to an oral glucose challenge was found to result in smaller increases in the plasma 
glucose level at minute 30 (p < 0.05) and minute 120 (p < 0.01) during the oral glucose 
tolerance test of a participant 41.  Another study of 20 healthy individuals revealed that 
green tea containing 300 mg of EGCG reduced carbohydrate absorption following a 
carbohydrate rich meal by up to 25% (p = 0.014) by assessing breath hydrogen and 
carbon dioxide concentrations 42.  Fukino et al. studied the intake of 456 mg catechins in 
60 Japanese participants with borderline diabetes.  They found that consuming the high 
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 dose of catechins for two months significantly reduced hemoglobin A1C    (p = 0.03), a 
marker for long-term glucose control 43.  Participants in this study were allowed to 
continue drinking green tea while in the study, and although this was accounted for, can 
pose as a potential barrier to clear results. 
Overall, the effects of green tea on glucose metabolism in type 2 diabetes appear to be 
mediated by several mechanisms.  GTCs may decrease carbohydrate absorption and 
decrease hepatic glucose production.  Other mechanistic ideas for the role of GTCs in 
type 2 diabetes include increased insulin secretion and insulin sensitivity, as well as an 
increased uptake of glucose into skeletal muscle 44. 
Green Tea & Cardiovascular Disease 
Cardiovascular health is another major concern and a field that has been investigated to a 
large degree.  There are many in vitro and animal studies exploring the mechanisms by 
which GTCs may improve cardiovascular health. For example, a popular Chinese green 
tea called Dragon Well Tea has been shown to significantly suppress lipoxygenase 
activity and inhibit endothelial-cell induced LDL oxidation (p = 0.001) 45.  This type of 
green tea has also been shown to lower the plasma cholesterol in Sprague-Dawley rats 
that have been made hypercholesterolemic through their diet.  This was achieved through 
increasing fecal bile acids and cholesterol excretion 46. Also, several studies have shown 
that green tea slows down atherosclerosis in animals 47-49.  Possible mechanisms for 
slowing down the rate of atherosclerosis include reduced plasma lipid peroxides and 
lower aortic cholesterol and triglyceride contents in animals given green tea supplements.  
12 
 
 A review by Cheng analyzing many in vitro and animal studies led to several suggested 
mechanisms in support of cardiovascular health through GTC intake.  These mechanisms 
include the ability of green tea to exhibit antioxidant activity, anti-inflammatory 
properties, inhibit vascular smooth muscle growth, counteract vasoconstriction, as well as 
prevent hypertension and stroke 50. 
Epidemiological studies have shown that green tea has a positive effect on cardiovascular 
health.  A large prospective cohort study performed in Japan following 40,530 adults 
without a history of stroke or coronary artery disease for 11 years found that green tea 
consumption was inversely associated with mortality due to cardiovascular disease (men 
drinking 3 to 4 cups/day: OR 0.88; 95% CI, 0.79-.98 and women drinking 3 to 4 
cups/day: OR 0.77 (95% CI: 0.67-0.89) 51.  Imai and Nakachi found an inverse 
relationship between green tea consumption and several markers for cardiovascular 
disease within 1,371 men.  The incidence of heart disease was 26.0, 29.4, and 39.8 per 
1000 in the population with a daily consumption of green tea greater than ten cups, 4 to 9 
cups, and less than three cups respectively.  Decreased serum concentrations for total 
cholesterol (p for trend < 0.001) and triglycerides (p for trend < 0.02) were found to be 
significantly associated with increased consumption of green tea. Increased proportion of 
high density lipoprotein cholesterol and decreased proportion of low and very low 
lipoprotein cholesterols were found to be associated with consumption of greater than 10 
cups per day (p for trend < 0.02)  52.   
Clinical trials have added to an understanding of the role green tea may play in 
cardiovascular health.  A four-week study followed 12 healthy male volunteers.  The 
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 participants consumed 600 ml of green tea daily.  The levels of oxidized low-density 
lipoprotein, a known biomarker to increase in the development of atherosclerosis, were 
significantly decreased after the four week time period of the study (p = 0.006) 53.   
Another study using 14 healthy women found that consuming a green tea supplement 
containing 375 mg catechins led to a reduction in the concentration of oxidized low-
density lipoprotein (p = 0.017) and modifications in vascular function (p = 0.02) 54. A 
meta-analysis by Zheng et al. reviewing 14 randomized control trials studying green tea 
consumption and the lipid profile of adults concluded that green tea consumption lowered 
the total cholesterol concentration (-7.20 mg/dL; 95% CI: -8.19, -6.21) and low-density 
lipoprotein cholesterol concentration (-2.19 mg/dL; 95% CI: -3.16, -1.21) in the blood of 
the participants in the studies reviewed 55.  There are few clinical studies showing 
promising results with green tea and its relation to cardiovascular health.  Larger and 
more in depth clinical trials will be needed to assess this multi-faceted disease. 
Green Tea & Cancer 
Perhaps the most well-known role of GTCs in human health is its role in cancer 
prevention.  Both in vitro and animal studies have revealed the ability of green tea to 
prevent cancer cell metastasis 56,57.  Animal studies have shown inhibition of 
tumorigenesis in the oral-digestive tract, lungs, skin, prostate, bladder, and mammary 
tissue 58.  The primary actions of EGCG in the inhibition of carcinogenesis are thought to 
be its ability to directly bind to receptors and other target proteins to inhibit key enzyme 
activities or affect signal-transduction pathways.  Also, the anti-oxidative functions of 
EGCG may be important to destroy reactive oxygen species at all carcinogenesis stages.   
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 A large number of epidemiological studies have looked at the association between green 
tea consumption and the risk of cancer of several organs.  Statistical analysis of these 
studies reveal that their results are not strong and neither confirm or deny what has been 
found in animal studies thus far.  Epidemiological studies have suggested a moderate 
protective effect of green tea against oral cancer, while data is inconsistent in regards to 
esophagus and stomach cancer.  The temperature of tea may play a role in this difference 
since the tea temperature has since been shown to be a factor in the development of these 
cancers 59.  Studies have also proved inconsistent in regards to colorectal, liver, 
pancreatic, lung, breast, prostate, and urinary bladder cancer making it hard to form a 
conclusion on the role of green tea in these organs.  There has been some evidence from a 
small case-control study that green tea may reduce the risk of leukemia 60.  Because this 
was a small, hospital based study design, more studies are needed to validate these 
results.  
There are many confounding factors within epidemiological studies such as diet, alcohol 
intake, smoking status, medications taken by participants, and activity level that can be 
more tightly controlled within a clinical trial leading to clearer results.  One clinical trial 
researched the effects of EGCG in the form of ointment or capsule in patients with 
cervical lesions infected with human papilloma virus.  An overall response rate of 69% to 
the treatment of green tea extracts in ointment or capsule form (p < 0.05) suggested that 
green tea extracts may be a potential therapy for human papilloma virus infected    
legions 61.  Lee et al. showed that green tea leaves were a useful source to slowly release 
catechins and theaflavins in the mouth.  This may help explain green tea’s potential role 
in the prevention of dental caries and oral cancer 62.  Clinical trials have been very limited 
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 thus far in subject sample size, gender, and age.  More research is needed in the area of 
GTCs and cancer.     
Biotransformation of Catechins 
Various studies have examined the bioavailability and biotransformation of GTCs.  
Fewer studies have investigated the biological activities of the metabolites of catechins 5.  
It has been confirmed through research that tea catechins undergo considerable 
biotransformation.  The extensive metabolism, including intestinal, microbial, and 
hepatic metabolism, of GTCs is most likely one of the reasons for its low bioavailability.  
Oral bioavailability of GTCs has been shown to be low in both animals 6,63 and      
humans 64,65.  Factors that may influence the low bioavailability and uptake of catechins 
include intestinal permeability and metabolism, transport inhibitors, efflux of catechins 
by multidrug resistance-associated proteins, and additional metabolism within the colon 
through microbial metabolism. The major metabolic pathways for catechins occur in the 
liver, kidneys, and gastrointestinal tract.  These major pathways include methylation, 
glucuronidation, sulfation, and ring-fission metabolism and will be discussed in further 
detail in an upcoming section of this literature review 6.  The major metabolic pathways 
of GTCs are shown in figure 3. 
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Figure 3: Major metabolic pathways of green tea catechins 5  
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 Methylation of GTC 
Studies have shown that methylation of GTCs is the major Phase II metabolic pathway 
leading to a variety of metabolites 6.  The enzyme responsible for the methylation of 
GTCs is catechol-O-methyltransferase (COMT).  COMT catalyzes the transfer of methyl 
groups from S-adenosylmethionine (SAM) to a hydroxyl group of a catechol or 
substituted catechols with Mg2+ present.  This generates O-methylated catechol and S-
adenosyl-L-homocysteine (SAH) 66.  Figure 4 shows the folate and methionine cycles 
where SAM is converted to SAH by COMT 67.  SAM is the methyl donor for COMT to 
methylate other substrates.  COMT is found distributed throughout the tissues of 
mammals that have been investigated thus far.  In rats and humans, the highest activity is 
found in the liver, and then the kidney and gastrointestinal tract 68.  COMT exists in both 
a soluble and membrane-bound form in mammals.  The soluble form of COMT is present 
in most tissues, while a membrane-bound form is the main form found in the human brain 
69.  The activity of COMT within erythrocytes has been shown to vary between species 
and is higher in rats and lower in humans 70,71.  COMT activity, specifically toward 
EGCG and EGC, has also been shown to be higher in rat liver cytosol than in human or 
mouse liver cytosol 72.   EC and EGC are good substrates for methylation by a placental 
cytosolic COMT, while ECG and EGCG are methylated at a far slower rate by the same 
enzyme 73.  Humans and mice are more similar, in general, than humans and rats in 
regards to COMT enzyme activity 5.  
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Figure 4: The folate and methionine cycles with COMT enzyme adapted                    
from reference 67 
 
 
The overall function of COMT is to eliminate possibly noxious or active catechol 
structures of endogenous or exogenous compounds.  The methylation of these structures 
decreases the hydrophilicity where it can then go on to be further sulfated or 
glucuronidated to be successfully eliminated from the body 68.  Physiological substrates 
for the COMT enzyme include 3,4-Dihydroxy-L-phenylalanine (L-DOPA), 
catecholamines, and catecholestrogens.  Flavonoids, such as catechins, are dietary 
products that can also be a substrate for COMT 74.  Certain compounds can inhibit the 
COMT enzyme and significantly affect the metabolism of the compounds able to act as 
substrates with COMT.  Selective COMT inhibitors, such as synthetic nitrocatechol 
compounds, are used in current therapies of Parkinson’s disease (PD) in combination 
with other treatments 75.  These inhibitors reduce COMT activity and increase the 
bioavailability of L-DOPA to help PD patients.  Flavonoids have been shown to inhibit      
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 COMT  76.  EGCG and its metabolites were shown to be powerful inhibitors of COMT 
enzyme mediated O-methylation of both EGC and L-DOPA 68.  It has also been revealed 
that tea catechins inhibit the O-methylation of endogenous catecholestrogens further 
displaying tea catechins and their metabolites may be inhibiting COMT 77.  These 
inhibitory effects of tea catechins on the activity of COMT can alter the rate of 
metabolism and methylation of tea catechins.  
There are various methylated catechin metabolites resulting from the COMT enzyme 
pathway.  Researchers have detected methylated metabolites including 3’- and 4’-O-
methyl-EC, 4’-O-methyl EGC, 4”-O-methyl EGC and EGCG, and 4’ and 4”-di-O-methyl 
EGCG from observations in vivo and in incubations with rat liver homogenates 78. The 
major metabolite found in the bile of the rats following oral EGCG administration was 4’ 
and 4”di-O-methyl EGCG 5.  Enzymology studies have shown similar metabolites 
formed with EGC being easily methylated to form 4’-O-methyl-(–)-EGC and EGCG to 
4”-O-methyl-(–)-EGCG or 4’, 4”-O-dimethyl-(–)-EGCG by rat liver cytosolic COMT 68.  
Sang et al. chemically synthesized several GTC metabolites in their lab and verified their 
structures in human plasma and urine samples using LC/MS.  These metabolites included 
4’-O-methyl EGC, 4”-O-methyl EGC, and 4’, 4”-di-O-methyl-EGCG.  The same 
researchers also confirmed that 4”-O-methyl EGC and 4’, 4”-di-O-methyl-EGCG were 
the major metabolites of EGC and EGCG in human plasma and urine in their studies 78. 
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 Factors affecting GTC methylation 
There are factors that may affect the methylation of GTCs.  Cytosolic protein 
concentration, concentration of S-adenosyl-L-methionine, incubation times, and 
incubation pH all affected methylation when investigating placental cytosolic COMT 73. 
There is indication that glucuronidation on the B-ring or D-ring of EGCG will 
considerably inhibit methylation on the same ring while glucuronidation on the A-ring of 
either EGCG or EGC will not affect methylation when COMT was studied in rodents 68.  
These studies also showed the concentration of the catechins were of importance.  Lower 
concentrations of EGCG lead to the dimethylated EGCG metabolite being the major 
product, and higher concentrations of EGCG lead to more monomethylated products 
being formed. 
Another factor that may affect methylation of GTC is a polymorphism in the gene coding 
for the COMT enzyme.  The COMT enzyme is coded for by a single gene.  This COMT 
gene encodes for both the membrane-bound COMT and the soluble COMT that are 
transcribed by the activation of two individual promoters.  A single nucleotide 
polymorphism (G to A) in codon 108 of the soluble COMT gene or codon 158 of the 
membrane-bound COMT gene results in a valine to methionine substitution in both forms 
of the COMT enzyme 79.  This polymorphism produces a high-, intermediate, and low-
activity form of COMT with genotypes of Val/Val (G/G), Met/Val (A/G), and Met/Met 
(A/A), respectively.  The polymorphism results in thermostability differences leading to a 
thermolabile low-activity COMT enzyme.  The high-activity enzyme is thermostable 80.  
There is a three to four times decrease in enzymatic activity between the high- and low-
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 activity COMT enzymes.   
Catechin Metabolism & COMT Genotype 
Several studies have examined the relationship between the COMT genotype and GTC 
metabolism and excretion in humans.  A cross-sectional analysis within the Shanghai 
Cohort Study evaluated whether urinary levels of GTC metabolites differed between 
participants with low-activity or high-activity genotypes among those who drank green 
tea daily 81.  A total of 18,244 men were enrolled in this study and interviewed upon 
enrollment to gain necessary information.  A non-fasted blood sample and a single-void 
urine sample were also taken at this interview.  Information regarding tea drinking was 
acquired at an in-person interview one year from the first interview held with each 
participant.  These annual interviews were acquired from 14,210 of the 14,531 
participants.  It was found that 95% of participants were exclusive green tea drinkers and 
had a mean daily intake of 8.3g of dry green tea leaves (three to four cups) per day.  The 
genotype distribution of COMT was 52.0% G/G, 40.6% A/G, and 7.4% A/A.  The 
distribution was found to be unrelated to the consumption of green tea by participants.  
The low activity allele was found to be in Hardy-Weinberg equilibrium.  It was 
discovered that the men with the homozygous A/A genotype of COMT had a statistically 
significant reduction in the levels of the urinary tea catechins EGC (p=0.047), 4’-MeEGC 
(p=0.049), M4 (p=0.037), and overall total tea polyphenols (p=0.007) in their spot urine 
compared with the men of A/G and G/G genotypes.  EC (p=0.057) and M6 (p=0.099) 
were found to have borderline statistically significant lower levels in the spot urines of 
the men with the A/A genotypes.  When stratified by level of green tea consumption, low 
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 consumers (less than 5g per day of green tea leaves) carrying the A/G or A/A genotype 
had a 35-45% reduction in urinary levels of 4’-MeEGC and EC.  However, urinary 
excretion rates of urinary catechins and their metabolites were similar between COMT 
genotypes of high consumers (greater than 5g per day of green tea leaves).  This may 
indicate that at high doses of GTCs, the COMT genotype will not play a significant role 
in altering green tea metabolism. 
A clinical, double-blind, placebo-controlled study supplemented participants with GTC 
and obtained 24-hour urine collections 82.  A total of sixty-four out of eighty-three 
subjects completed the study.  Each participant was on a placebo supplement for a six-
week period and a treatment supplement for a six-week period with a two week wash out 
period.  The decaffeinated green tea treatment supplement contained 530 mg catechins 
(40.71% EGCG, 16.27% EGC, 8.74%EC, 6.02% ECG).  A 24-hour urine collection was 
done by the participant approximately a week before starting and ending supplement.  24-
hour urine collections were mixed into a homogenous solution and measured for EGC 
and 4’-O-methyl EGC.  Urinary excretion of the catechins remained unchanged for 
participants at baseline and post-intervention of the placebo.  The levels of EGC and 4’-
O-methyl EGC were found to be lower in the men of the G/G genotype group compared 
to the A/G and A/A genotypes (p<0.01).  The levels in the G/G genotype group were 
roughly half the amount found in the other genotypes.  COMT distribution of participants 
was not reported.  These results differ from the cross-sectional analysis from the 
Shanghai Cohort Study. 
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 A recent clinical trial investigated fifty healthy, male subjects (25 G/G and 25 A/A) using 
a randomized, placebo-controlled, double-blind, crossover design 83.  530 mg DGT 
(43.0% EGCG, 10.9% EGC, 8.3%EC, 8.9% ECG) was given to participants after 48 
hours of a low flavonoid diet.  A 24-hour urine collection was taken starting at the time of 
ingestion of study supplement to measure for EGC and 4’-O-methyl EGC in the urine.  
The urine collection was split into the first 5.5 hours and the last 18.5 hours.  It was 
discovered that the A/A COMT genotype had significantly lower urinary concentrations 
of 4’-O-methyl EGC in the 5.5-hour urinary collections compared to the G/G genotype 
taking DGT.  There were no genotype differences seen in the 18.5-hour collection.  
Dividing up the hours of the 24-hour urine collection could indicate that a difference in 
COMT genotype may be meaningful only in the first several hours of metabolism.  These 
results suggest that the timing of sample collection may be crucial to give accurate insight 
on GTC metabolism.   
COMT, Green Tea, & Breast Cancer Risk 
COMT could have the ability to reduce the cancer preventive effects of GTCs because of 
its varying activity due to the polymorphism.  A case-control study of Asian-American 
women discovered a reduced risk of breast cancer (adjusted OR, 0.48; 95% CI; 0.29-
0.77) in women who consumed green tea and were of A/A or A/G COMT genotype.  
However, there was no difference in breast cancer risk between green tea drinkers and 
non-tea drinkers for those that were homozygous G/G COMT genotype 84.  A larger, more 
recent epidemiological study looked at 3,454 breast cancer cases and 3,474 controls.  It 
found that the COMT genotype did not significantly modify an association between green 
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 tea drinking and breast cancer risk.  Menopausal status did not change this  
insignificance 85.  The role COMT plays in catechin metabolism and disease is still 
unclear.  
Glucuronidation & Sulfation of GTC  
A second pathway in Phase II metabolism of GTCs is glucuronidation catalyzed by a 
group of enzymes called UDP-glucuronosyltransferases (UGT).  UGT catalyzes the 
binding of glucuronic acid from UDP-glucuronic acid on structurally unrelated 
constituents with a carboxyl, hydroxyl, amine, or thiol group 78.  The glucuronidation of 
EGCG and EGC in human, mouse, and rat microsomes were studied by Lu and 
researchers.  They also explored the glucuronidation of the catechins in nine different 
human UGT isozymes expressed in insect cells 85.  Four EGCG (EGCG-7-O-glucuronide, 
EGCG-4”-O- glucuronide, EGCG-3”-O- glucuronide, and EGCG-3’-O- glucuronide), 
and two EGC (EGC-3’-O- glucuronide and EGC-7-O-glucuronide) glucuronide 
metabolites were biosynthesized.  EGCG-4”-O-glucuronide was shown to be the major 
EGCG glucuronide formed in all incubations.  This major metabolite was most readily 
formed in mouse small intestinal microsomes, followed in decreasing catalytic efficiency 
order by mouse liver, human liver, rat liver, and rat small intestine.  The glucuronidation 
of EGC was much lower than EGCG.  The glucuronidation of EGC to EGC-3’-O-
glucuronide had its greatest catalytic efficiency in the mouse liver microsomes followed 
by the human liver, rat liver, and then rat and mouse small intestine.  In both 
glucuronidation reactions of EGC and EGCG, mice appear to be more similar to humans 
than rats 86.  EC has been reported to form only two glucuronide metabolites in rat liver 
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 microsomes, while showing no signs of being glucuronidated in the human liver, small 
intestines, or colon microsomes 87.   
It has been found that UGT1A1, 1A8, and 1A9 have the highest activity toward EGCG 
by using recombinant human UGT enzymes 6.  Human UGT1A1 is present in human 
liver and intestine, while UGT1A9 is present in human liver and kidney.  UGT1A8 is 
only found in the intestine 6.  Intestinal specific UGT1A8 has the highest catalytic 
efficiency toward EGCG, however it has low activity with EGC.  The activities of 
UGT1A1, 1A3, and 1A8 are much lower when the major glucuronidation site of EGCG 
is occupied by a methyl group.  4”-methylation can enhance glucuronidation of EGCG at 
this D-ring site with the UGT1A9 enzyme 78.   
GTCs can also undergo sulfation. The enzymes responsible for this are sulfotransferases 
(SULT).  These enzymes catalyze the transfer of a sulfate group from a donor molecule 
to an acceptor alcohol or amine 78.  EC undergoes sulfation catalyzed by both human and 
rat liver and intestinal enzymes in cytosol.  The human liver is shown to be the most 
efficient 86. SULT1A1 is mainly responsible for the sulfation of EC in the human liver 
cytosol, and both SULT1A1 and SULT1A3 contribute to sulfation of EC in the intestine.  
It has been shown that EGCG is sulfated by human, mouse, and rat liver cytosol.  It is 
time and concentration dependent with the rat cytosol having the greatest activity 
followed by the mouse and human liver cytosol 72. 
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 Microbial Metabolism of GTC 
The human colon contains roughly 1000 bacterial species amounting to over 100 trillion 
bacteria in total in the large intestine.  This microflora has vast catalytic and hydrolytic 
potential for dietary compounds including polyphenols 78.  Colonic microflora can 
catalyze the breakdown of polyphenols into simple compounds such as phenolic acids 
and their glycine conjugates.  Studies have shown that the amount of GTCs absorbed in 
the small intestine is relatively small.  This would imply that the majority of GTCs 
ingested, including those that have been absorbed and conjugated by other enzymes in the 
tissues, will reach the large intestine and be metabolized by the intestinal flora 6.  It has 
been reported that tea catechins are metabolized by the colonic microflora forming the 
following major ring fission products: 5-(3’,4’,5’-trihydroxyphenyl)-γ-valerolactone 
(M4), 5-(3’,4’-dihydroxyphenyl)-γ-valerolactone (M6), and 5-(3’,5’-dihydroxyphenyl)-γ-
valerolactone (M6’) 77. These same ring fission products have been identified in both 
human urine and plasma after the ingestion of 20 mg/kg decaffeinated green tea 
approximately 13 hours after the consumption of tea 88.   
Following consumption of 200 mg EGCG, peak urine concentrations of 8, 4, and 8 µM 
have been verified for M4, M6, and M6’, respectively.  M6 has been shown to form 
during anaerobic incubation of EGC and EC with human intestinal bacteria 78.  M4, M6, 
and M6’ have all been shown to be produced as a result of anaerobic fermentation of 
EGC, EC, and ECG with human fecal microflora 72.  Further degradation of these ring 
fission products would result in the formation of lower weight phenolic acids by the 
intestinal flora 78.  Several other microbial metabolites have been identified in human 
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 urine samples.  These include 4-hydroxybenzoic acid, 3,4-dihydroxybenzioc acid, 3-
methoxy-4-hydroxy-hippuric acid, and 3-methoxy-4-hydroxybenzoic acid 89. These 
particular metabolites may need to be researched further to determine if they have any 
beneficial properties on human health.  
Biological Activities of Catechin Metabolites 
The metabolites of GTCs have been studied for their own biological activities.  The 
radical scavenging ability of the glucuronide metabolites of EGCG and EGC has been 
investigated 86.  There were varying scavenging abilities depending on the metabolite.  
EGC had greater radical scavenging ability compared with both EGC-3’-glucuronide and 
EGC-7-glucuronide.  However, the glucuronide metabolites of EGCG were more active 
than EGC and its glucuronide metabolites.  EGCG-3’-glucuronide and EGCG-3”-
glucuronide had equal radical scavenging abilities to EGCG, while EGCG-7-glucuronide 
and EGCG-4”-glucuronide were less active than EGCG.  Studies have also examined the 
growth inhibitory activity of EGCG against cancer cell lines.  There was a 40% growth 
inhibition when HT-29 human colon and KYSE150 human esophageal cancer cell were 
treated with M4.  When these same cells were treated with EGCG, there was a 50% 
growth inhibition 90.  HCT-116 human colon cancer cells, INT-407 human, and IEC-6 rat 
immortalized intestinal cell lines were not all sensitive to M4 growth inhibitory effects.  
It has been reported that methylated metabolites 4’-O-MeEGCG and 4”-O-methylEGCG 
have decreased growth inhibitory and pro-apoptotic activity compared to EGCG 91.  The 
methylated metabolites also had reduced Fe (III)-reducing power, and 4’-O-MeEGCG 
had decreased H2O2-producing ability.  These studies show that the various GTC 
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 metabolites could play an important role in various biological activities but appears that 
the parent GTC compounds have an overall stronger activity.    
GTCs and their metabolites have been studied for their difference in inhibitory effects on 
the COMT-mediated methylation of hydroxyestradiol.  ECGC has been shown to be a 
potent inhibitor of COMT.  Both 4”-O-methylEGCG and 4’,4”-di-O-methylEGCG were 
less potent than EGCG at inhibiting COMT.  EGCG-7-glucuronide was just slightly less 
potent at inhibiting COMT, while EGCG-3’-glucuronide, EGCG-3”-glucuronide, and 
EGCG-4”-glucuronide were significantly less potent.  EGC was also significantly less 
potent than EGCG, and methylation at the 4’-hydroxyl group did not significantly affect 
the inhibitory activity of EGC 92.  Overall, these studies seem to indicate that EGCG has 
the strongest inhibiting qualities.  
Pharmacokinetics of GTC 
The pharmacokinetics and bioavailability of GTCs have been studied more extensively in 
rat and mice animal models than in humans.  The plasma concentration-time curves of 
EGCG, EGC, and EC have been fit into a two-compartment pharmacokinetic model with 
elimination half-lives (t1/2) of 212, 45, and 41 minutes, respectively, following 
intravenous administration of decaffeinated green tea in rats.  The absolute bioavailability 
of EGCG, EGC, and EC were 0.1, 13.7, and 31.2%, respectively, following an 
intragastric administration of decaffeinated green tea 93.  Lambert et al. discovered the 
oral bioavailability of unchanged EGCG to be about 15.8% in mice 94.  Other studies have 
reported very low bioavailability of EGCG in rats 6,95. Another related study found EGCG 
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 levels in the plasma and tissues between 0.0003% and 0.45% of the ingested EGCG 96.  
Both of these present the poor bioavailability of EGCG in rats.   Excretion in the feces 
has been shown to be the major route of elimination of radioactive labeled EGCG.  After 
the administration of 4-[4-3H]EGCG intravenously to bile-duct-cannulated rats, only 2% 
of the radioactivity was excreted in the urine, and about 77% was excreted in the bile 
within 48 hours 93.  After the administration of [3H]EGCG intragastrically to mice, about 
6.5% of the radioactivity was excreted in urine and 35% in feces within 24 hours 97.   
Several studies have investigated the pharmacokinetics of GTC in human participants.  
An earlier study used different amount of DGT to determine blood and urine levels of 
GTCs in humans 98.  Each gram of DGT contained 73 mg EGCG, 68 mg EGC, 22 mg 
ECG, and 25 mg EC.  GTC reached peak plasma levels (Tmax) in 1.5-2.5 hours after 
consumption of 1.5 g of DGT.  The average maximum plasma concentration of the GTCs 
(Cmax) was 0.71, 1.8, 0.65 µM of EGCG, EGC, and EC, respectively.  Cmax values 
increased 2.7- to 3.4- fold when the dosage was increased from 1.5 g to 3.0 g DGT.  
Increasing the dose to 4.0 g DGT did not increase the Cmax values significantly.  After 
oral administration of 1.5-4.0 g DGT, t1/2 of EGCG, EGC, and EC were 4.9-5.5, 2.5-2.8, 
3.2-5.7 h, respectively.   
Chow et al. administered a single-dose of Polyphenon E or EGCG to twenty, healthy 
participants in a cross-over design study 99.   Polyphenon E is a DGT extract that contains 
80-98% total catechins with EGCG accounting for 50-75% of total supplement material.  
Each Polyphenon E capsule in this study contained 200 mg EGCG, 37 mg EGC, and 31 
mg EC.  It was found equal doses of EGCG in pure form or in Polyphenol E led to 
similar pharmacokinetics of EGCG. Figures 5 and 6 show the plasma concentrations of 
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 unchanged EGCG in participants at a dose of 200, 400, 600, and 800 mg EGCG or 
EGCG in Polyphenon E.  The average Cmax after a 200, 400, 600, and 800 mg dose of 
EGCG were 0.16, 0.24, 0.37, and 0.96 µM, respectively.  The average Cmax after a 200, 
400, 600, and 800 mg dose of Polyphenon E containing equivalent amounts of EGCG 
were 0.16, 0.27, 0.36, and 0.82 µM, respectively.  Only EGCG was detected in the 
plasma after EGCG administration.  When plasma samples were treated with β-
glucuronidase and sulfatase deconjugating enzymes after a dose of EGCG, EGCG levels 
did not change significantly suggesting that EGCG is mostly in the unchanged form in 
the plasma.  EGCG levels were detected, and EGCG and EC were low or undetectable in 
human plasma after a Polyphenon E dose.  When plasma samples were treated with 
deconjugating enzymes after a dose of Polyphenon E, EGCG levels still did not change 
much, but EGC and EC level increased significantly.  This suggests that EGC and EC are 
present mostly in the conjugated forms in the plasma and that the bioavailability of the 
GTCs are relatively low.   
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Figure 5: Average EGCG concentration (ng/ml) vs. time after oral administration of 
EGCG 99 
 
Figure 6: Average EGCG concentration (ng/ml) vs. time after oral administration99 
of Polyphenon E 99 
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 Another study administered 20 mg/kg green tea or decaffeinated green tea to eight 
healthy adult volunteers 100.  It was found that EGCG was mostly found in the free form 
in the plasma, similar to other studies.  EGC and EC were mostly in the conjugated form. 
77% of EGCG, 31% of EGC, and 21% of EC were found to be in free form in the one-
hour plasma samples.  After five hours, 64% of EGCG and 40-50% of EGC and EC were 
in free from.  The catechins not in free form were conjugated and most were in the 
glucuronide form.  In the 24-hour urine collections, tea catechins were found to be more 
than 95% in conjugated form.  Greater than 90% of urinary catechins were excreted in the 
first eight hours, showing that extensive glucuronidation and sulfation occurs to these 
catechins similar to other findings.  A higher percentage of EGC and EC appeared in the 
urine when green tea was taken in the decaffeinated form.  3.3% of EGC and 8.9% of EC 
was detected in the urine while only 2.3% of EGC and 4.6% of EC appeared when 
regular green tea was consumed.  In all cases, EGCG was present in trace or non-
detectable amounts in the urine 101.  This implies the significant metabolism EGCG 
undergoes within the body.  The pharmacokinetics of conjugated metabolites of EGC and 
(-)-EC were not affected by repeated green tea administration.   
Following the administration of one cup decaffeinated green tea or pure catechins in four 
healthy, male subjects, more than 80% of GTCs were found in the conjugate forms in the 
one-hour plasma samples 102.  In plasma samples, 58-72% of EGCG was in a conjugated 
sulfate form, 12-28% was in free form, and 8-19% was in glucuronide form.   57-71% of 
EGC was in the glucuronide form, 23-36% in sulfate form, and 3-13% was in free form.  
EC was almost found exclusively in the conjugated forms with roughly 33% 
glucuronided and 77% sulfated.  ECG was not detected in the plasma.  Maximum urinary 
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 excretion of EGC and EC occurred three to six hours after administration of GTCs.  The 
majority of EGC and EC occurred three to six hours after administration of GTCs.  
EGCG and ECG were not detected in urine.  Sulfate and glucuronide forms of EGC and 
EC were present in about a 2:1 ratio.  Free EC was not detected, and less that 1% of EGC 
was present in unconjugated form.  Methylated metabolites were not assessed in this 
study.     
Chow et al. assessed the pharmacokinetics in 40 healthy men and women supplemented 
daily with 400 mg or 800 mg of free EGCG or as part of a GTC supplement 103.  At the 
end of week 4, the area under the curve (AUC) was reported to be 145.6 min µg/ml with 
supplementation of 800 mg free EGCG.  The average peak plasma concentration of the 
GTCs (Cmax) was 390.3 ng/ml, the average time it took to reach the maximum plasma 
concentration (Tmax) was 210.0 min, and the biological half-life (t1/2) was 158.9 min at the 
end of week 4.  It was discovered that there was a greater than 60% increase in the AUC 
of free EGCG after four weeks of supplementation compared to the first dose AUC in the 
group with an 800 mg dose (p < 0.05).  There was no significant change in the subjects 
with a 400 mg EGCG dose.  Inhibition of intestinal flora metabolism, intestinal efflux of 
EGCG, or methylation via the COMT enzyme may play a role in this effect.   
One clinical trial has assessed the pharmacokinetic of GTCs and the effect of the COMT 
polymorphism 104. Seven men and seven women each with the high-activity COMT 
genotype and three men and three women having the low-activity genotype were 
recruited. Two capsules of decaffeinated green tea extract totaling 448 mg EGCG were 
given to participants, a standardized breakfast was given one hour after supplementation 
34 
 
 to avoid stomach upset.  Blood samples were taken at 0, 30, 60, 90, 120, 150, 180, 240, 
360, and 480 minutes after capsule consumption.  A pharmacokinetic analysis was done 
for all participants for EC, EGC, ECG, EGCG, and 4’-O-methyl EGCG plasma 
concentrations.  There were no significant differences found for Cmax, Tmax, AUC, EGCG 
half-life absorption, and EGCG half-life elimination between the two A/A and G/G 
genotypes. 4’-O-methyl EGCG was found to have a higher Cmax and AUC in the A/A 
genotype, although these results were not statistically significant.  No other significant 
parametric differences were found between the two COMT genotype groups. 
Overall, studies in human have shown that GTCs are metabolized rapidly in humans.  
Average Cmax were between one and three hours after oral consumption, reach Tmax 
concentrations in the sub- or low µM range, and t1/2 appear to be on average 2-4 hours 105. 
Factors Affecting Bioavailability of GTC 
The oral bioavailability of tea catechins have been shown to be quite low in rodents and 
humans in pharmacokinetic studies. The poor bioavailability of tea catechins can be a 
result of instability within digestive conditions, poor transcellular transport, and the rapid 
metabolism that is followed by excretion 6,106.  Almost total degradation of EGCG and 
roughly 80% total catechin loss has been observed in simulated digestion of simple tea 
infusions. Instability of catechins has been demonstrated in authentic intestinal juice and 
buffered systems above a pH of 7.4 107. EC and ECG have been shown to be less sensitive 
to simulated digestion.  GTCs have been shown to be extremely unstable in neutral or 
alkaline conditions in general 6.  This degradation in the small intestine limits catechin 
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 uptake and bioavailability.  The low bioavailability of some catechins may be attributed 
to the comparatively high molecular weight and the large number of hydrogen-bond 
donating hydroxyl groups.  This follows Lipinski’s rule of 5 which states that compounds 
that have five or more hydrogen bond donors, or ten or more hydrogen bond acceptors, or 
a molecular weight greater than 500 will usually have poor bioavailability.  This is 
because of the large size of the molecule and the formation of a large hydrogen shell 108.    
Phase III metabolism is called active efflux and has been shown to limit the 
bioavailability of tea polyphenols.  The multidrug resistance-associated proteins (MRPs) 
are the ATP dependent efflux transporters that carry out this active efflux and are 
expressed in many tissues.  MRPs and active efflux may play an important role in 
restricting the bioavailability of tea catechins.  MRP1 is located on the basolateral side of 
cells and is present in nearly all tissues. It transports compounds like tea polyphenols 
from the interior of a cell into the interstitial space.  MRP2 is located on the apical 
surface of the intestine, liver, and kidney where it transports constituents from the 
bloodstream into the lumen, bile, and urine, respectively 72. Studies have shown that the 
MRP inhibitor, indomethacin, causes an increase in the intracellular accumulation of 
EGCG, EGCG 4”-O-methyl-EGCG, or 4’, 4”-di-O-mehtyl-EGCG by 10-, 11-, or 3-fold, 
respectively, in canine kidney MDCKII cells expressing MRP1. In the same way, an 
MRP2 inhibitor, MK-571, produced an intracellular increase in the levels of EGCG, 
EGCG 4”-O-methyl-EGCG, or 4’, 4”-di-O-mehtyl-EGCG by 10-, 15-, or 12-fold, 
respectively, in MDCKII cells expressing MRP2 109.  It has been demonstrated that ECG 
is a substrate for a monocarboxylate transporter, MCT, in Caco-2 cells.  When MCT-1 is 
inhibited by benzoic acid or phloretin in these cells, the uptake of ECG is reduced 110.   
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 There are factors that can help increase catechin bioavailability.  Studies in Caco-2 cell 
models have shown that sugar, ascorbic acid, and even xylitol may modulate and increase 
catechin bioavailability 111,112.  Sugar and ascorbic acid together increased bioavailability 
greater than sugar or ascorbic acid alone in rats, and xylitol and ascorbic acid together 
increased bioavailability greater than xylitol or ascorbic acid alone in cells.   It has been 
shown by Chow et al. that a greater oral bioavailability can be attained when free 
catechins are taken on an empty stomach after an overnight fast in humans.  Human 
participants administered Polyphenon E on an empty stomach after an overnight fast 
resulted in greater plasma levels of free EGCG, EGC, and ECG.  Fasting state did not 
affect total EGC levels but did significantly increase total levels of EGCG and decrease 
total levels of EC in the plasma 113.  These studies show that tea consumption practices 
and formulation factors could result in greater tea catechin bioavailability.   
Overall, the gastrointestinal tract plays a crucial role in the bioavailability of GTCs as 
they metabolize.   Metabolites that are formed in the small intestines and transported back 
to the intestinal lumen will make their way to the large intestine to be metabolized further 
by the gut microflora.  The microflora of an individual therefore, is a factor that needs to 
be considered when addressing GTC metabolism.  These metabolites may be reabsorbed 
or passed out through the feces.  Figure 5 shows a summary of possible pathways of 
GTCs in a human body.   
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Figure 7: Suggested outcomes of GTC metabolism in humans adapted from reference 6 
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 Concluding Words: A Need for Research  
There is a lack of research investigating the interaction of a green tea treatment, catechin 
metabolism, and the COMT genotype in humans.  One epidemiological study with a 
larger sample size has assessed urinary catechin levels among differing COMT genotypes 
indicating COMT may play a role in catechin metabolism.  Only a few clinical trials have 
investigated plasma or urinary catechin metabolism and have reported mixed results.  All 
studies had small sample sizes and most did not assess the intermediate genotype.     
The understanding of the GTC metabolism and biotransformation is essential for gaining 
knowledge into how green tea may protect against human disease.  The complexities of 
green tea absorption and metabolism have yet to be fully understood, and addressing the 
COMT genotype may help further the understanding of catechin metabolism.  A better 
experimental design with a larger sample size investigating both plasma and urinary 
catechin metabolism in all three COMT genotypes will be important to achieve this.   
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 INTRODUCTION 
Tea is one of the most commonly consumed beverages in the world.  Brewed from the 
dried leaves of Camellia sinensis 113, green tea has been shown to have high levels of 
polyphenols due to minimal oxidation during the processing of fresh tea leaves. 
Catechins, the major polyphenolic compounds in green tea, have been investigated 
extensively in relation to the treatment or prevention of chronic diseases such as diabetes, 
cardiovascular disease, and cancer 72.  
The four main types of catechins found in fresh tea leaves are (-)-epicatechin (EC), (-)-
epicatechin gallate (ECG), (-)-epigallocatechin (EGC), and (-)-epigallocatechin gallate 
(EGCG) 7.  A typical cup of brewed green tea contains 30-42% of catechins by dry 
weight 8. EGCG is the most abundant and widely studied catechin of green tea and could 
account for 50% to 80% of the total catechins in green tea 6.  Many of the biological 
effects of green tea consumption are associated with its catechin content, particularly 
EGCG.   
Green tea catechins (GTCs) undergo considerable biotransformation and have been 
shown to have low bioavailability in both animals 6,63 and humans 64,65.  Therefore, 
understanding the efficacy of GTCs in vivo is quite complex.  The major metabolic 
pathways for catechins include methylation, glucuronidation, sulfation, and ring-fission 
metabolism 6.  O-methylation is a major Phase II metabolic pathway of GTC metabolism 
and is catalyzed by the enzyme catechol-O-methyltransferase (COMT).  The COMT 
enzyme is coded for by a single gene.  A single nucleotide polymorphism (G to A 
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 substitution) in codon 108/158 of the soluble COMT or codon 158 of the membrane-
bound COMT results in a valine to methionine substitution in the enzyme.  This 
polymorphism causes a three to four times decrease in enzymatic activity in vitro 
producing a high (G/G), intermediate (A/G), and low-activity (A/A) form of the COMT 
enzyme 79.   
Interestingly, epidemiological studies have shown interactions between these 
polymorphisms in the COMT enzyme and the association of green tea consumption with 
breast cancer risk. A case-control study of Asian-American women 84 found green tea 
consumption to be associated with reduced risk of breast cancer in women who carried 
one low-activity COMT allele (adjusted OR, 0.82; 95% CI, 0.64-1.06) or both low-
activity alleles (adjusted OR, 0.84; 95% CI, 0.54-1.30).  A possible explanation for this 
observation is that individuals with a variant genotype resulting in decreased COMT 
activity would metabolize GTCs at a lower rate, and thus, receive more of the potential 
benefits from GTCs due to greater exposure.  Consistent with this hypothesis, a recent 
cross-sectional analysis among men who drank green tea daily within the Shanghai 
Cohort Study 81 discovered that homozygous low-activity COMT individuals showed a 
35-45% reduction in total tea polyphenol levels in spot urine samples compared with men 
with intermediate or homozygous high-activity genotypes (p = 0.007).   
On the other hand, several human intervention trials have assessed green tea intake, 
metabolism, and COMT genotype with varying results 82,83,104.  The largest clinical trial 
performed to date with 71 subjects in an intention-to-treat design found 24-hour urinary 
levels of EGC and 4’-O-methyl EGC in the homozygous high-activity genotype to be 
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 decreased by about half compared to the other genotypes 82.  These results differ from 
those found in the cross-sectional analysis of the Shanghai Cohort Study.  Miller et al. 
discovered 25% lower urinary concentration of 4’-O-methyl EGC in the first 5.5 hours of 
24-hour urine collections in the low-activity COMT genotype compared to the 
participants with high-activity COMT genotypes 83  A pharmacokinetic study on 
individuals consuming GTC and with different COMT genotypes found no differences in 
pharmacokinetic parameters in the plasma of subjects 104. 
The role COMT genotype plays in GTC metabolism in humans remains unclear.  There 
have been no large clinical trials performed to date assessing the impact of differing 
COMT genotypes on the metabolism and excretion of GTCs.  The primary aim of this 
study was to determine if COMT polymorphisms will modify the excretion and plasma 
levels of GTCs in postmenopausal women at high risk for breast cancer after dietary 
supplementation of green tea extract (GTE; containing 1222 mg total catechins/day 
including 830 mg EGCG/day) for 12 months.  It is hypothesized that total plasma and 
urinary GTCs, and urinary methylated GTCs will be reduced in individuals with the 
homozygous low-activity COMT genotype. 
MATERIALS & METHODS  
Study participants and recruitment 
The study sample used for this research is a subsample of 180 participants from a larger 
parent study, “Green Tea and Reduction of Breast Cancer Risk,” the Minnesota Green 
Tea Study (Clinical Trial Registration: clinicaltrials.gov identifier: NCT00917735).  The 
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 parent study is a large, randomized, double-blind, placebo-controlled, clinical trial 
investigating the effects of green tea supplementation on biomarkers of breast cancer risk. 
Mammographic density, reproductive hormones, insulin-like growth factor axis proteins, 
and oxidative stress will be assessed in over 800 healthy, postmenopausal women at high 
risk for breast cancer due to elevated breast density.  A possible modifying effect of 
COMT genotype on all biomarkers will additionally be investigated.   
All participants for this sub-study were recruited from the Breast Center at the University 
of Minnesota Medical Center, Fairview Southdale Breast Center, or Fairview Maple 
Grove Breast Center between July 2009 and September 2011 in the Minneapolis, MN 
metropolitan area.  The study radiologist supervised the identification of women aged 50 
to 70 years old with “heterogeneously dense” or “extremely dense” breasts as indicated 
by the American College of Radiology 114. “Heterogeneously dense” breasts are 
approximately 51-75% glandular tissue, while “extremely dense” breasts have more than 
75% glandular tissue.  A recruitment letter approved by the Institutional Review Board 
(IRB Approval Code Number: 0806M36121) explaining the purpose of the study was 
mailed to prospective participants.  Interested participants called a screening telephone 
number, and a screening questionnaire was administered to the potential participant over 
the phone.  Potential subjects who met further eligibility criteria attended an in-person 
orientation.   Potential participants then attended a screening visit where COMT genotype 
and final eligibility status was determined.  Eligible participants were randomized into 
either the GTE or placebo group and scheduled for their baseline clinic visit.  This study 
was approved by the University of Minnesota’s Institutional Review Board and written 
informed consent was obtained from all subjects prior to the screening visit. 
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 Inclusion criteria included: healthy women 50 to 70 years old; last menstrual period 
greater than one year ago; “heterogeneously dense” or extremely dense” breasts; and 
willingness to avoid consumption of green tea.  Exclusionary criteria included positive 
serological markers for hepatitis B or C; elevated liver enzymes (above 1.5 times the 
upper limit of normal for the University of Minnesota-Fairview Hospital Laboratory); 
hormone modification therapy, hormone replacement therapy, selective estrogen-receptor 
modulator, or aromatase inhibitor usage in the last six months; current smoker; body 
mass index (BMI) less than 19 or greater than 40 kg/m2; weight change greater than 10 
pounds in the previous year; participation in weight gain or weight loss studies; history of 
breast cancer or proliferative breast disease; history of ovarian cancer; history of any 
cancer in the last five years; presence of breast implants; greater than seven alcoholic 
beverages consumed per week; greater than one cup of green tea consumed per week; or 
use of chemopreventative agents in the last six months. 
For this sub-study, 180 participants were randomly chosen from those who had 
completed the study as of November 2012. From the treatment and placebo groups, 30 
high-activity, 30 intermediate-activity and 30 low-activity COMT genotype participants 
were selected. 
Study design 
The parent study was a randomized, double-blind, placebo-controlled study with 
participants randomized based on their COMT genotype and treatment group (Figure 1).  
Randomization was performed through the Investigational Drug Services (IDS) at the 
University of Minnesota based on COMT genotype and treatment group.  A total of 1,084 
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 participants (289 high-activity, 451 intermediate-activity, and 344 low-activity) were 
randomized into the parent study with a withdrawal rate of 12.4%.  The participants for 
this sub-study analysis were randomly chosen from completed participants by the study 
biostatistician in November 2012.  At this time a total of 328 participants had completed 
the parent study (64 high-activity, 173 intermediate-activity, and 86 low-activity).     
For one year, participants consumed two capsules twice daily (for total of four capsules). 
They were instructed to continue with their normal diets and lifestyles, and they came in 
monthly to the clinic for collection of biological samples.  
For this study, participants provided a fasting blood sample and a 24-hour urine 
collection at baseline, six-month and twelve-month clinic visits.  A health history 
questionnaire was given to the participants at the screening clinic visit and was completed 
and returned to study staff at the baseline clinic visit.  Compliance was verified through 
study logs in which participants recorded capsules consumed and pill counts were also 
conducted on returned study supplement capsules at clinic visits.   
Dietary Supplements  
The GTE and placebo capsules were manufactured by Corban Laboratories (Plymouth, 
USA). They were encapsulated in a two-piece, green, opaque, size “0” cellulose capsule 
(V cap).  High-performance liquid chromatography (HPLC) determined that each GTE 
capsule was comprised of EGCG (207.5 mg), ECG (62.4 mg), EC (23.0 mg), and EC 
(23.0 mg).  Table 1 shows the contents of the GTE supplement.  Magnesium stearate (2 
mg) was added as a flow agent.  The placebo capsule appeared identical to the green tea 
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 capsule but contained maltodextrin (50.0%), microcrystalline cellulose (49.5%), and 
magnesium stearate (0.05%).  Participants received a three month supply of study 
supplement at their baseline clinic visit in three prescription bottles with corresponding 
prescription labels distributed by the IDS.  Participants were asked to take two capsules 
in the morning with breakfast and two capsules in the evening with dinner for a daily 
dose of approximately 830 mg EGCG.  Participants received a new supply of supplement 
every three months. 
DNA isolation and COMT genotyping  
COMT genotyping was performed at the University of Minnesota Molecular 
Epidemiology and Biomarkers Research Laboratory. The screening blood sample was 
centrifuged at 3,000 rpm for 10 minutes at 4°C.  The buffy coat layer was transferred to 
an aliquot tube with 0.5 ml normal saline and stored at -80°C until analysis.  DNA was 
extracted from buffy coats at time of analysis using a DNeasy Blood & Tissue Kit 
column method (QIAGEN Sample and Assay Technologies) according to manufactures 
protocol.  DNA was eluted in 200µl nanopure water (Applied Biosystems) and quantified 
by nanodrop.  Ten µl of the sample DNA was diluted to approximately 5ng/µl and added 
to the wells of a PCR plate.  An assay mix consisting of PCR master mix and Genotyping 
assay mix (Qiagen) was also added to the wells.  Genomic DNA (5.625µl per well) was 
used for PCR amplification.   PCR was carried out on Applied Biosystem 7900 Real-
Time PCR system.  The initial thermal cycler step was 2 minutes at 50°C followed by 10 
minutes at 95°C. Next, 50 cycles were carried out at 95°C for 15 seconds and at 60°C for 
60 seconds.  The plate was then analyzed by the Allelic discrimination protocol in the 
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 same machine, and the output generated determined the genotype of the wells.  A no 
template blank control and 3 wells of Corriell cell lines (GM15327, GM15080, and 
GM15334) were used as controls to be compared to the experimental samples to identify 
the genotype at each locus (G/G, A/G, and A/A) on each plate.   
Urine collection and catechin analysis 
Participants were instructed to discard their first early morning urine (start time) the day 
prior to their clinic visit and collect all urine for 24 hours including the urine produced on 
the following day at the same time as the start time (end time).  Three grams of ascorbic 
acid were added to the three-liter collection jug at the start of urine collection.  
Participants were asked to keep the urine sample refrigerated and avoid alcohol 
consumption during collection.  Collected urine samples were mixed into a homogenous 
solution and measured for total volume using graduated cylinders.  Ten µl ascorbic acid-
EDTA was added to aliquoted samples and stored at -80°C within 2 hours of receiving 
collection from participants until analysis.  Urinary EC, EGC, methylated EGC, 5-
(3’,4’,5’-trihydroxyphenyl)-γ-valerolactone (M4), and 5-(3’,4’-dihydroxyphenyl)-γ-
valerolactone (M6) were measured in the laboratory of C.S. Yang, Rutgers University, 
according to validated methods 98,102.  In brief, the thawed urine samples were mixed with 
sodium phosphate buffer, ascorbic acid, EDTA, and a mixture of β-glucuronidase and 
sulfatase.  The mixture was incubated and the reaction stopped with1 ml of ethyl acetate.  
Seven hundred µl of organic phase was transferred to a microfuge tube after mixing and 
centrifugation.  A second extraction was obtained with 700 µl of ethyl acetate, and the 
combined 1.4 ml extract was processed and analyzed on a HPLC system.  The system 
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 consisted of an ESA Model 465 refrigerated autosampler, two ESA-580 dual-piston 
pumps, and an ESA 5500 coulochem electrode array system.  Standard tea catechins were 
used to assess the stability of the HPLC system.  Duplicate measures were made for all 
samples as well as urinary creatinine concentrations.  Every six samples included one 
intraday standard.  Each set of samples also included an interday standard that was run in 
the middle of the set.  A total of 22 sets were run, and coefficient of variations (CVs) 
were calculated from these samples.  If the intraday CV was greater than 10% in the 
urine, samples were re-run.  Intraday CV means for M4, EGC, M6, EC, and Me-EGC 
were 4.1%, 3.3%, 3.0%, 2.6%, and 3.4%, respectively.  Interday CV means were 3.6%, 
3.3%, 5.7%, 3.4%, and 4.3% respectively.  Urinary tea catechin concentrations are 
expressed as the weight of analyte per gram of creatinine to adjust for the volume of 
urine.   
Plasma collection and analysis  
Fasted plasma samples were collected and aliquoted, and ascorbic acid-EDTA (100 µl) 
was added to aliquots that were stored at -80°C until analysis.  Plasma EC, EGC, ECG, 
and EGCG were measured in samples according to the validated methods of Yang et al 
115.  Briefly, the thawed plasma samples were incubated with a mixture of β-
glucuronidase and sulfatase to determine total catechin content.  The reaction was 
stopped by the addition of methylene chloride. To analyze free catechin content, the β-
glucuronidase and sulfatase mixture was excluded from incubation.  The reaction mixture 
was then extracted two times with ethyl acetate.  Ten µl EDTA solution was added to 
these two ethyl acetate extractions and evaporated to dryness in a vacuum centrifuge 
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 concentrator.  Residues were re-dissolved in 100 µl acetonitrile aqueous solution and 
centrifuged.  Prepared samples were analyzed on the same HPLC system as urinary 
catechin analysis.  Duplicate measures were made for all samples.  CVs were calculated 
similarly to urine.  If the intraday CV was greater than 12%, samples were re-run.  
Intraday CV means for EGC, EC, EGCG, and ECG were 7.3%, 6.3%, 8.2%, and 8.4%, 
respectively.  Interday CV means were 6.6%, 5.6%, 6.5%, 7.2%, respectively.   
Statistical analysis 
Urinary GTC metabolites were expressed relative to creatinine by weight (nmol/mg Cr). 
Plasma catechin concentrations were expressed as nmol/ml.  Formal statistical testing 
was completed on logarithmically transformed values because GTC metabolites were not 
normally distributed.      
ANOVA was used to compare catechin levels at baseline between treatment and placebo 
groups.  Mixed model analyses were used to compare metabolite levels between groups 
at months 6 and 12 and between time points.  ANOVA was used to compare levels of 
metabolites across discrete categories of demographic and lifestyle variables using age 
(year) as a covariate.  For this analysis, measurements were done at the 12-month time 
point.  The multivariate regression method was used when assessing the effect of COMT 
genotype on levels of urinary and plasma catechin metabolites at month 12.  Adjustments 
were made for age (year), ever cigarette smoking (no, yes), alcohol drinking (no, yes), 
and tea drinking (no, yes).   
50 
 
 Statistical analyses were carried out using SAS version 9.1 (SAS Institute Inc., Cary, NC) 
statistical software package.  All reported p values are two-sided and p < 0.05 was 
considered statistically significant.  
RESULTS 
There were a total of 180 participants in this sub-study.  Thirty subjects with the high-
activity COMT genotype, thirty with intermediate-activity COMT genotype, and thirty 
with low-activity COMT genotype from each of the placebo and treatment groups were 
analyzed.  Table 2 shows baseline levels of urinary and plasma catechins in the treatment 
and placebo groups. Catechins levels did not differ between groups with the exception of 
plasma EC, which was significantly higher in the treatment group (p = 0.044). Table 3 
shows the effect of treatment and time on urinary and plasma catechins.  All metabolites 
were significantly higher in the treatment group at both months 6 and 12 (p < 0.001), 
with the exception of plasma EGC, which did not differ between groups (p = 0.10).  
There were no significant differences in catechins between the 6 and 12-month time 
points with the exception of urinary M4, which was significantly higher at month 12 
compared to month 6 (p = 0.01).   
The remaining statistical analyses were performed in the 90 participants in the treatment 
group at month 12.  Table 4 shows the levels of urinary metabolites by selected 
demographic and lifestyle factors for the treatment group.  Table 5 shows the levels of 
plasma metabolites by selected demographics and lifestyle factors by treatment group.  
There was a statistically significant association between race and urinary EGC, urinary 
Me-EGC, and plasma EGCG.  Urinary EGC and Me-EGC were significantly higher than 
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 two participants that identified themselves as a race other than white.  These same two 
participants had significantly lower levels of plasma EGCG.  There was also a significant 
association between participants who had smoked previously in their lifetime and plasma 
EC levels, with decreased levels of plasma EC in subjects who had ever smoked 
compared subjects who had not.  Level of education and alcohol consumption did not 
affect levels of GTC metabolites in plasma or urine.   
No statistically significant differences were found in any urinary or plasma catechin 
metabolite measurements between homozygous high-activity COMT genotype and 
homozygous low-activity COMT genotype, although there may be trends toward higher 
urinary EGC and M6 in the homozygous low group (p = 0.12 and 0.10, respectively, 
Table 6).  Additionally, no differences were found in any of the GTC metabolite between 
genotypes when the high-, intermediate-, and low-activity COMT genotype were 
compared, although there was a trend toward higher M6 in the intermediate and low 
groups (p = 0.14, Table 6).      
Spearman correlation coefficients were calculated between urinary and plasma catechin 
metabolite levels (Table 7).  A number of metabolites were strongly correlated within 
plasma and within urine, but few were correlated between plasma and urine. 
DISCUSSION 
This study investigated urinary and plasma catechin levels, and the modifying effect of 
differing COMT genotypes, in 180 postmenopausal women consuming either placebo or 
1222 mg catechins/day (containing 830 mg EGCG/day) for one year.  Participants 
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 consumed 611 mg total catechins (containing 415 mg of EGCG) twice daily.  This is 
similar to drinking approximately six to seven 250 ml cups of green tea per day 115. 
Compliance was assessed in all participants through pill counts.  There were 405 capsules 
distributed every three months and remaining capsules in bottles were counted at the next 
clinic visit.  There was an average of 52 pills returned at the end of every three months 
with a calculated 97.2% average compliance rate. 
The placebo and treatment groups were similar at baseline, with the only difference being 
that plasma EC was higher in the treatment group (Table 2).  All metabolites were 
significantly higher in the treatment group at month 12, with the exception of plasma 
EGC, which did not differ between groups (Table 3).  This is likely due to the low level 
of EGC in the GTC capsules.  
Surprisingly, there was no effect of genotype on urinary or plasma catechins in the GTC 
group.  This finding is not consistent with that of previous research.  A clinical trial by 
Brown et al.82 assessed catechin excretion in 24-hour urine samples in 71 male subjects 
taking roughly 430 mg EGCG per day in a 6-week cross-over study using a decaffeinated 
green tea (DGT) supplement.  Urinary levels of EGC and 4’-O-methyl EGC were lower 
in the high-activity COMT genotype compared to the intermediate- and low-activity 
genotype (p = 0.01 and 0.03, respectively).  Another study was reported in 25 
homozygous low-activity COMT and 25 homozygous high-activity COMT healthy males 
who had followed a low flavonoid diet for 48 hours and then were given a one-time DGT 
supplement containing approximately 460 mg EGCG 82. This study found significantly 
reduced levels of 4’-O-methyl EGC in the first 5.5 hours of 24-hour urine collections in 
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 the low-activity COMT genotype (p = 0.05).  Similar to our results, metabolite levels in 
24-hour collections did not differ between groups 83.  It is possible that a full 24-hour 
urine collection may dilute GTC metabolites making differences undetectable.  However, 
24-hour collections are known for being a better representation than spot urine samples 
for metabolism in general. In a smaller study by Lee et al., one cup of DGT containing 88 
mg EGCG, 82 mg EGC, 33 mg ECG, and 32 mg EC was administered to four, healthy 
males and 24-hour urine collections were obtained in three hour time increments 102.  It 
was discovered that the maximum level of EGC and EC metabolite urinary excretion 
happened three to six hours after ingestion of GTCs.  Almost all EGC and EC metabolites 
were excreted within the first nine hours of the 24-hour collection.  The timing of sample 
collection may be an important variable and incremental 24-hour urine collection may 
reveal more information.       
One other recent epidemiological study investigated the association of COMT genotype 
with GTC metabolism.  A cross-sectional analysis within the Shanghai Cohort Study 81 of 
18,244 men who daily consumed brewed green tea revealed that subjects with the low-
activity COMT genotype had a statistically significant reduction in overall total tea 
polyphenols (p = 0.007) in a spot urine compared to subjects with intermediate- and high-
activity genotypes.  Spot urine samples were taken an average of three hours after intake 
of a participant’s last meal.  Green tea is commonly consumed after meals allowing 
metabolites of GTCs to be at their maximum concentration in the urine samples.  Further 
analysis showed low consumers of green tea (less than 5g/day of green tea leaves) 
carrying the intermediate- or high-activity genotype had a 35-45% reduction in urinary 
levels of -O-methyl EGC and EC.  However, urinary excretion rates of urinary catechins 
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 and their metabolites were similar between COMT genotypes in high consumers (greater 
than 5g/day of green tea leaves).  Perhaps the COMT genotype only has a significant 
effect on GTC metabolism at moderate consumption levels of catechins.   
Simple pharmacokinetic studies investigating variable dosing of GTC have been 
previously done without taking COMT genotype into account.  GTC have been shown to 
have limited absorption and are in the nanomolar ranges in the plasma and urine 116.  
Chow et al. assessed the pharmacokinetics in 40 healthy men and women supplemented 
daily with 400 mg or 800 mg of free EGCG or as part of a GTC supplement 103.  It was 
discovered that there was a greater than 60% increase in the calculated area under the 
curve (AUC) of free EGCG after four weeks of 800 mg supplementation EGCG, free or 
in GTC supplement, compared to the AUC from the first dose at week 0.  Subjects taking 
only 400 mg per day of ECGC did not see a change in the AUC from week 0 to week 4.  
Inhibition of intestinal flora metabolism, intestinal efflux of EGCG, or methylation via 
the COMT enzyme could have caused the increase in AUC at a higher EGCG dosing.  
EGCG and its metabolites have been shown to be COMT enzyme inhibitors of O-
methylation of EGC, 66 and higher doses of GTC could stimulate this effect to a larger 
degree.       
There are a number of major differences between previous studies and the present study.  
Former clinical trials have only investigated male subjects, populations of different 
ethnicities, lower doses of GTC, fewer participants, and a shorter duration of green tea 
supplementation compared to the present study.   The one epidemiological study was able 
to assess many participants, but intake of GTCs may not have been as accurately assessed 
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 as in a clinical trial because diet and environment were not as tightly controlled.  While 
there are a number of major differences between the present study and previous 
investigations, perhaps one of notable importance is the dosage of the green tea 
supplementation.  The cross-sectional investigation within the Shanghai Cohort Study 
assessed tea intake based on dry tea leaves used per week for brewed infusions, while 
clinical studies used supplements with already known GTC contents.  It is challenging to 
compare the catechin content in brewed tea infusions to GTC supplements due to 
variability in tea source and brewing time.  Standardizing for a 1% infusion (1g tea 
leaves/ 100ml boiling water), there is approximately 350 mg EGCG in 5g of dried tea 
leaves.  This is the level of tea ingested where an effect of COMT genotype was seen 81.  
There is a possibility for recall bias in the cross-sectional study, and level of tea intake 
where COMT genotype may have an effect may be influenced by this.   Adjustment for 
brewing time is not taken into account since the majority of tea flavonoids are extracted 
shortly after brewing 117.  The 350 mg dose of EGCG is similar to previous clinical trials 
detecting a difference in catechin excretion and varying COMT genotypes 82,83.  The 830 
mg EGCG in the present study is far above previous amounts investigated.  It is possible 
that there is a threshold of GTC intake in which the COMT polymorphism plays a role in 
altering the metabolism of GTC.  Future studies may need to provide different dosages of 
GTC to their participants to investigate this further.    
There were some limitations to this study.  Health history questionnaires were completed 
by the participants alone.  In-person interviews may have provided more accurate 
demographic data.  Also, participants were not required to follow a low flavonoid diet 
due to the long period of this study.  The analysis of 24-hour urines may have diluted any 
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 increase in catechin excretion, compared with collecting urine in the few hours after 
supplement consumption. Similarly, fasting blood draws were taken 10 or more hours 
after consumption of the GTC.  
In conclusion, there were no associations found between the COMT genotype status of 
postmenopausal women and the urinary and plasma levels of green tea catechins.  The 
dosing of GTCs and the timing of biological sample collection are important factors that 
need consideration.  Future trials may need to evaluate differing GTC dosing when 
assessing the effect of COMT genotype and GTC metabolism.  
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 Figure 1: Parent Study (Minnesota Green Tea Study) Design 
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Table 1. Composition of Green Tea Extract Capsules  
Compound 
Percent of 
Extract  
Content Per 
Capsule (mg) 
Daily Catechin 
Dose *  
(mg/day) 
Epigallocatechin gallate 
(EGCG) 53.0 207.5 830.0 
Epicatechin gallate (ECG) 15.9 62.4 249.6 
Epicatechin (EC) 5.88 23.0 92.0 
Epigallocatechin (EGC) 1.6 6.2 24.7 
Gallocatechin Gallate (GCG) 1.63 6.4 25.5 
Catechin <0.01 0.04 <0.16 
Caffeine  <1.0 3.9  
Magnesium Stearate <0.5 2  
Total Catechins  305.5 1221.8 
 
* Study dose consisted of two capsules taken twice daily with breakfast and dinner 
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 Table 2. Comparison of Baseline Catechins (Geometric Means (95% Confidence 
Interval)) between Treatment and Placebo Groups * 
Catechin Treatment         
(n = 90) 
Placebo  
(n = 90) 
P 
value 
Urinary Catechins      
     M4, nmol/mg creatinine 0.06 (0.04-0.10) 0.06 (0.04-0.10) 0.89 
     EGC, nmol/mg creatinine 0.16 (0.10-0.22) 0.18 (0.12-0.24) 0.62 
     M6, nmol/mg creatinine 7.6 (5.6-10.3) 9.2 (6.8-12.4) 0.39 
     EC, nmol/mg creatinine 0.76 (0.56-0.98) 0.76 (0.56-0.98) 0.94 
    Me-EGC, nmol/mg 
creatinine 
0.12 (0.06-0.20) 0.14 (0.08-0.22) 0.71 
Plasma Catechins       
     EGC, nM 1.3 (0.92-1.7) 1.2 (0.84-1.6) 0.73 
     EC, nM 1.7 (1.3-2.2) 1.1 (0.78-1.5) 0.04 
     EGCG, nM 3.5 (2.7-4.5) 3.9 (3.1-5.0) 0.52 
     ECG, nM 0.90 (0.70-1.14) 0.94 (0.74-1.18) 0.80 
 
* Geometric means were derived from analysis of variance. 
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 Table 3. Urinary and Plasma Catechins by Treatment Group and Time Point (Geometric Means (95% Confidence Interval)) * 
Catechin Treatment (n = 90) Placebo (n = 90) P Value for Overall 
Effect † 
Month 6 Month 12 Month 6 Month 12 Treatment‡ Time 
Urinary catechins       
     M4, nmol/mg creatinine 1.4  
(1.1-1.7) 
1.9  
(1.5-2.3) 
0.10  
(-0.02-0.24) 
0.12  
(-0.12-0.26) 
<0.001 0.01 
     EGC, nmol/mg creatinine 0.48  
(0.38-0.58) 
0.48  
(0.40-0.56) 
0.18  
(0.10-0.28) 
0.18  
(0.10-0.24) 
<0.001 0.95 
     M6, nmol/mg creatinine 41.1  
(31.7-53.1) 
45.2  
(34.9-58.4) 
8.2  
(6.1-10.8) 
9.4 
(7.1-12.4) 
<0.001 0.11 
     EC, nmol/mg creatinine 10.9  
(9.7-12.1)  
10.9  
(9.7-12.3) 
0.68  
(0.52-0.86) 
0.7 
(0.54-0.94) 
<0.001 0.70 
     Me-EGC, nmol/mg creatinine 0.72  
(0.56-0.88) 
0.72  
(0.56-0.92) 
0.12  
(0.02-0.24) 
0.20  
(0.08-0.32) 
<0.001 0.37 
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Plasma measurements 
      
     EGC, nM 2.0  
(1.5-2.6) 
2.0  
(1.5-2.7) 
1.4  
(1.0-1.9) 
1.6  
(1.1-2.2) 
0.096 0.585 
     EC, nM 18.3  
(15.1-22.2) 
17.2  
(14.0-21.2) 
1.2  
(0.82-1.6) 
1.5  
(1.0-2.0) 
<0.001 0.667 
     EGCG, nM 43.0  
(33.4-55.2) 
41.5  
(32.4-53.0) 
4.2  
(3.1-5.6) 
4.6  
(3.4-6.2) 
<0.001 0.806 
     ECG, nM 19.4  
(16.0-23.4) 
20.3  
(17.1-24.0) 
0.96  
(0.64-1.4) 
0.94  
(0.64-1.3) 
<0.001 0.858 
* Geometric means were derived from analysis of variance. 
† Based on mixed model analyses. 
‡ 12 month time points were used in the comparisons between treatments. 
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 Table 4. Urinary Catechins in Participants Consuming Green Tea Catechins, by Demographic and Lifestyle Factors                  
(n=90, Geometric Means (95% Confidence Interval))* 
 # Subjects 
(%) 
 Urinary Catechin (nmol/mg creatinine) †  
 M4                            EGC M6 EC Me-EGC 
Race       
     White 88 (97.8)     1.90 
   (1.4-2.4) 
       0.46 
      (0.38-0.54) 
44.3 
(35.2-55.6) 
11.0 
(9.8-12.3) 
0.70 
(0.54-0.88) 
     Others 2 (2.2)    1.78 
   (-0.1-7.6) 
      1.64 
      (0.78-2.9) 
105.8 
(22.7-480.9) 
7.78 
(3.3-17.0) 
2.48 
(0.78-5.8) 
     P value‡     0.95       0.004 0.27 0.40 0.04 
Education        
     High school 6 (6.7)   1.80 
  (0.46-4.3) 
      0.80 
      (0.44-1.3) 
45.40 
(18.6-108.8) 
12.94 
(8.3-19.9) 
1.08 
(0.42-2.1) 
     College  84 (93.3)   1.90 
  (1.4-2.4) 
      0.46 
      (0.38-0.54) 
45.14 
(35.7-57.1) 
10.78 
(9.69-12.1) 
0.70 
(0.54-0.88) 
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      P value‡  0.91       0.08                0.99 0.44              0.32  
Ever smoking        
     No 60 (66.7) 1.74 
(1.2-2.4) 
       0.50 
       (0.38-0.60) 
40.32 
(30.5-53.0) 
10.7 
(9.3-12.4) 
0.72 
(0.52-0.94) 
 
     Yes 30 (33.3) 2.24 
(1.4-3.3) 
       0.44 
      (0.30-0.60) 
56.60 
(38.3-83.5) 
11.3 
(9.2-13.8) 
0.74 
(0.46-1.1) 
 
     P value‡  0.36        0.63 0.17 0.68 0.90  
Alcohol Intake         
     No 21 (23.3) 1.58 
(0.82-2.7) 
      0.54 
      (0.36-0.76) 
53.68 
(33.3-86.2) 
12.28 
(9.7-15.6) 
0.76 
(0.42-1.2) 
 
     Yes 69 (76.7) 2.00 
(1.5-2.6) 
      0.46 
      (0.36-0.56) 
42.84 
(33.6-55.5) 
10.54 
(9.2-12.0) 
0.72 
(0.52-0.92) 
 
     P value‡  0.46       0.44 0.42 0.28 0.83  
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 Tea drinking 
     No 35 (38.9) 1.78 
(1.1-2.6) 
      0.46 
      (0.32-0.62) 
48.90 
(33.9-70.4) 
11.42 
(9.5-13.7) 
0.84 
(0.56-1.2) 
 
     Yes 55 (61.1) 1.96 
   (1.4-2.7) 
      0.48 
     (0.38-0.60) 
42.92 
(32.0-57.4) 
10.62 
(9.2-12.3) 
0.66 
(0.46-0.88) 
 
P value‡      0.71      0.79 0.59 0.55 0.34  
                                
 
  *All geometric means were derived from analysis of covariance with age (years) as a covariate. 
†Measurements from 12 month timepoint was used in the analyses. 
‡P values were derived from analyses of covariance with adjustment for age. 
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 Table 5. Plasma Catechins in Participants Consuming Green Tea Catechins, by Demographic and Lifestyle Factors                     
(n=90, Geometric Means (95% Confidence Interval))* 
 # Subjects 
(%) 
                            Plasma Catechin, nM† 
 EGC EC EGCG ECG 
Race       
     White 88 (97.8)  2.0 
(1.5-2.8) 
17.8 
(14.0-22.6) 
43.3 
(32.9-56.8) 
20.8 
(16.9-25.5) 
     Others 2 (2.2)  2.6 
(-0.12-13.6) 
3.7 
(0.02-20.9) 
5.9 
(0.14-40.6) 
6.3 
(0.98-26.1) 
     P value‡   0.82 0.09 0.048 0.11 
Education       
     High school 6 (6.7)  4.5 
(1.5-11.1) 
39.8 
(16.2-96.2) 
57.9 
(19.8-166.0) 
23.8 
(10.7-51.7) 
     College or above 84 (93.3)  1.9 
(1.4-2.6) 
16.2 
(12.7-20.7) 
40.5 
(30.4-53.8) 
20.0 
(16.2-24.7) 
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      P value‡   0.14 0.06 0.52 0.68 
Ever smoking       
     No 60 (66.7)  2.0 
(1.2-2.9) 
20.6 
(15.4-27.4) 
49.7 
(35.6-69.1) 
22.2 
(17.3-28.4) 
     Yes 30 (33.3)  2.1 
(1.2-3.5) 
12.0 
(7.8-18.2) 
28.9 
(17.9-46.4) 
16.9 
(11.8-24.1) 
     P value‡   0.90 0.04 0.07 0.23 
Alcohol drinking       
     No 21 (23.3)  1.9 
(0.9-3.5) 
12.3 
(7.3-20.4) 
41.3 
(23.0-73.5) 
19.4 
(12.6-29.8) 
     Yes 69 (76.7)  2.1 
(1.4-2.9) 
19.1 
(14.5-25.0) 
41.6 
(30.2-57.0) 
20.5 
(16.2-25.9) 
     P value‡   0.82 0.14 0.98 0.83 
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 Tea drinking 
     No 35 (38.9)  2.34 
(1.4-3.7) 
13.3 
(9.0-19.5) 
36.2 
(23.1-56.3) 
22.4 
(16.1-31.0) 
     Yes 55 (61.1)  1.88 
(1.2-2.8) 
20.3 
(15.0-27.4) 
45.3 
(31.8-64.3) 
19.0 
(14.6-24.7) 
     P value‡  0.49 0.10 0.44 0.45 
 
*All geometric means were derived from analysis of covariance with age (years) as a covariate. 
†Measurements from 12 month timepoint was used in the analyses. 
‡P values were derived from analyses of covariance with adjustment for age. 
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 Table 6.  Effects of COMT Genotype on Urinary and Plasma Catechins in Participants Consuming Green tea Catechins at 
month 12 (n=90, Geometric Means (95% Confidence Interval)) * 
                            COMT genotype activity P value†      P value‡ 
     H vs I vs L   High (n=30) Intermediate 
(n=30) 
  Low (n=30) High vs Low 
Urinary      
     M4, nmol/mg creatinine 1.9 (1.1-2.9) 1.7 (1.0-2.8) 2.0 (1.1-3.9) 0.88 0.96 
     EGC, nmol/mg creatinine 0.40 (0.24-0.56) 0.58 (0.40-0.78) 0.52(0.34-0.70) 0.32 0.12 
     M6, nmol/mg creatinine 39.2 (25.7-59.5) 58.5 (38.3-89.1) 61.3 (38.8-96.5) 0.14 0.10 
     EC, nmol/mg creatinine 11.0 (8.9-13.6) 12.5 (10.1-15.5) 11.0 (8.7-13.9) 1.00 0.58 
     Me-EGC, nmol/mg creatinine 0.66 (0.36-1.0) 0.84 (0.52-1.2) 0.78 (0.44-1.2) 0.60 0.42 
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 Plasma 
     EGC, nM 2.5 (1.4-4.1) 1.6 (0.78-2.9) 2.1 (1.0-3.7) 0.66 0.38 
     EC, nM 15.2 (9.8-23.5) 13.6 (8.6-21.2) 12.2 (7.4-19.7) 0.48 0.54 
     EGCG, nM 40.6 (24.2-67.5) 35.4 (20.9-59.5) 35.9 (20.3-63.0) 0.74 0.67 
     ECG, nM         18.2 (12.3-26.5) 18.2 (12.3-26.8) 22.0 (14.4-33.2) 0.49 0.70 
*Geometric means were derived from analysis of covariance with adjustments for age (year), ever cigarette smoking (no, yes),                       
alcohol drinking (no, yes), and tea drinking (no, yes). 
†P values were derived from multivariate regression models that compared the high COMT activity group with low activity groups                    
with the adjustments for all variables listed above. 
‡P values were derived from multivariate regression models that compared the high COMT activity group with intermediate and                      
low activity groups combined with the adjustments for all variables listed above. 
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Table 7. Spearman Correlation Coefficients between Urinary and Plasma Catechin 
Metabolites in Participants who Consumed Green Tea Catechins (n = 90)* 
           Urinary Catechins Plasma Catechins 
  M4 EGC M6 EC Me-
EGC 
EGC EC EGCG ECG 
Urinary 
Catechins 
M4 1.00 -
0.11 
0.231 -0.04 -
0.231 
-
0.15 
-0.05 0.07 0.05 
EGC   1.00 0.373 0.433 0.613 0.05 0.221 0.05 0.07 
M6   1.00 0.453 0.393 -
0.06 
-0.03 -0.03 -
0.004 
EC    1.00 0.423 0.11 0.272 0.08 0.15 
Me-
EGC 
    1.00 0.03 0.19 0.08 0.12 
Plasma 
Catechins 
EGC      1.00 0.353 0.16 0.10 
EC       1.00 0.743 0.573 
EGCG        1.00 0.803 
ECG         1.00 
*12 month time points were used in the analyses. 
12-sided P < 0.05; 22-sided P < 0.01; 32-sided P < 0.001. 
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 Name of caller ______________________________ Subject ID# ________________  
Phone (h) _______________ (w) ______________Email ________________________ 
Interviewer __________________________________   Date _______/______/______   
 
Phone Interview Questions: Green Tea Study 
1. To verify your identity, what is your date of birth? _____/_____/_____ 
2. Is this your first time contacting the Green Tea Study? ____________ 
3. What is your age?  _______ (50-70) 
4. Do you use tobacco products? ______ **Includes nicotine cessation products 
containing nicotine** 
5. When was your last menstrual period? _____/_____/_____    (must be at least 1 yr 
ago) 
6. What was the location and date of your last mammogram? _____/______/______  
____________________________________________________________________ 
7. Have you ever had breast cancer or proliferative breast disease? ________   
Proliferative breast disease, also called hyperplasia, is an overgrowth of breast cells 
diagnosed with a needle or surgical biopsy.  It is not a cancerous condition but 
usually requires more frequent breast exams to examine the breast tissue. 
8. Have you ever had ovarian cancer? ________   
9. Have you been diagnosed with any other form of cancer in the last 5 years? ______ 
**Basal and Squamous cell skin cancer are acceptable** 
10. Have you been on any of the following medications at any time during the past 6 
months? 
The individual qualifies for the study if NONE of these drugs have been taken in 
the past 6 months.         Y/N 
• Hormone Replacement Therapy 
           (For menopause symptoms)       _______     
• Tamoxifen   
(For breast cancer treatment or risk reduction)    _______     
• Raloxifene   
           (Osteoporosis treatment or risk reduction, or breast cancer risk reduction) 
                     _______     
• Aromatase Inhibitors 
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            Such as Arimidex, Aromasin, or Femara (For breast cancer treatment)   
          _______    
• Methotrexate or Enbrel                 
(For rheumatoid arthritis)       _______   
11. During the past 6 months, have you taken any medications regularly?  _______ 
If so, what are they?  
            
            
 
12. Do you have any chronic health problems? _______   
If so, what are they?  
            
            
**Per Protocol: if a subject has any of the conditions below they are not eligible 
to participate in the study. ** 
• Diabetes?   
 
• Hyperthyroidism?   
 
• Uncontrolled high blood pressure (hypertension)?    
  
• Crohn’s or Ulcerative Colitis:  ___ 
 
 
13. How tall are you? ______ What do you weigh? _____   
 
Calculate BMI ________ (19-35)   BMI = m/kg2  (1 lb. = 2.2 kg; 1 in. = 
0.0254 m) 
14. Has your weight changed in the past year? _______   
 
If so, how much? ______________ (<10 lbs past year) 
 
15.  Do you consume alcohol? _____ If so, how much? _________________ 
 (< 7 drinks/week; 1 drink = 5 oz. wine, 12 oz. beer, or 1.5 oz. 80-proof distilled 
spirits) 
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16.  Do you consume tea?  _______ If so, what kind?  
________________________________ 
 If you consume green tea, how often? __________ (Less than one cup/wk) 
17.  Are you able to come to the Human Nutrition Research Clinic on the St. Paul campus 
of the University of Minnesota, first thing in the morning, before breakfast?    YES
 NO 
 
 
18.  If you are interested in the study, can you commit to monthly visits to the Human 
Nutrition Research Clinic over the 12 months of the study?  For most visits, you will 
be able to come at the time of your choosing.  Three visits (at months 0, 6, and 12) 
will require you to have fasted since 10:00 the night before.  YES 
 NO 
 
 
19.  What is the best time to reach you? ______________________________________ 
 
 
20.  Would you prefer to be contacted by phone or email? ________________________ 
 
 
Congratulations!  You have met the preliminary requirements to participate in our Green 
Tea and Breast Cancer Risk Reduction Study. 
~OR~ 
Thank you very much for your time and interest.  Unfortunately, you do not qualify for 
our study for the following reasons: 
 
            
             
Thank you again, and have a great day. 
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 • If caller meets requirements, describe the study to them. 
 
 
Our study will look at breast cancer risk through the use of biological markers such as 
breast density.  We will be providing women that meet our criteria with either a green tea 
extract or placebo (inactive capsule) every day for one year.  We will be measuring 
several biological factors from your blood and urine that can help indicate your risk for 
breast cancer. 
Would you like to hear more information?     
Another variable involved in our study is the genetic difference between women.  
Differences in specific genes may affect how a woman responds to the green tea extract.  
We will be conducting a genetic test at the screening visit to confirm your eligibility for 
this study.  We will also test you for exposure to the hepatitis B and C viruses and 
measure your liver function before you can participate in the study.  These are routine 
tests that require about 2 to 4 tablespoons of blood withdrawn from your arm.  The blood 
will be drawn by nurses at the Human Nutrition Research Clinic at the University of 
Minnesota in St. Paul.  The results will be available in 2-4 weeks, and you will be 
notified if you meet the criteria for our study.  At that point, you will be able to schedule 
appointments at the clinic for the entire year of the study at your convenience, keeping in 
mind that 3 appointments—at months 0, 6, and 12—will require you to have been fasting 
since 10 o’clock the night before, so these appointments will be in the morning (between 
7:30 and 10).  If you do not meet the criteria for our study, you will be informed and 
compensated for your time. 
Would you like to hear more information?      
I will give you a brief description of the study.  If you would like to participate, we can 
schedule an orientation session to explain the study in more detail and answer all the 
questions you may have.  As part of a clinical trial, you will be randomly assigned to 
consume either a green tea extract or placebo capsule twice a day for one year.  During 
one year, biological markers from your blood and urine associated with breast cancer risk 
will be evaluated throughout fourteen clinic visits at the Human Nutrition Research 
Clinic (HNRC) of the University of Minnesota. Each clinic visit can take 0.5-1.5 hours. 
During each clinic visit, your weight, blood pressure, heart rate, and respiratory rate will 
be measured. Your waist and hip circumferences will also be measured at the second and 
last (fourteenth) clinic visits. Each clinic visit involves drawing a little more than 1 
teaspoon to 4 tablespoons blood depending on the clinic visit. For 3 visits, at the month 0, 
month 6, and month 12, you will need to have been fasting since 10 pm the night before 
your clinic visit. You will collect your entire 24 hour urine at the baseline, month 6, and 
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 12 and will bring collected urine in provided jugs to the HRNC for the clinic visits 2, 8, 
and 14.You will also complete a food frequency questionnaire, which is a survey about 
your eating habits that takes approximately 60 minutes. Your first routine mammogram 
will be compared with the mammogram that you are normally scheduled for during the 
following year, at the end of study. Finally, you will be asked to avoid drinking green tea 
during the study period so we will be able to assess the exact effect of consumed green 
tea extract. 
 
• Would you like to come to an orientation to learn more about participating in our 
study? 
 
Circle one of each of the following: 
 
   Status:              Preferred contact:     Orientation session: 
 
 ELIGIBLE        EMAIL     
_____/_____/______ 
 
INELIGIBLE       PHONE     
_________________ 
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Telephone Screening Questionnaire Eligibility Information 
 
Question 7: Restricted Medications 
Eligible if subject uses local cream, ring, 
or suppository no more than 3 days per 
week, & plans to continue therapy 
throughout the year of the study.  
(NO oral estrogens).  
 
ELIGIBLE: 
Cream: Estrace 
 Ogen 
 Ortho Dienestrol 
 Premarin                            
(Vaginal ONLY. No oral). 
Tablet: Vagifem 
Ring:  Estring 
Femring 
IUD: Mirena 
 
INELIGIBLE:  
Patch:  Alora 
 Climara 
 Esclim 
 Estraderm 
 Vivelle 
 Vivelle-Dot 
Gel: Estrogel 
Cream: Estrasorb 
------------------------------------------------- 
Question 8: Regular medications 
INELIGIBLE:  
- Warfarin (Coumadin) 
- Methotrexate  
- Enbrel 
- Anti-coagulation meds 
-  More than 10 different  
    medications regularly. 
Less common medications; for 
reference: 
 
INELIGIBLE: Oral estrogen/estrogen-
progestin pills 
 
Activella 
Cenestin 
Estinyl 
Estrace (pill form) 
Estratab 
Femhrt 
Menest 
Ogen (pill form) 
Ortho-Est 
Ortho-Prefest 
Premarin (pill form) 
Premphase 
Prempro 
 
ELIGIBLE: Progestin-only pills 
 
Aygestin 
Cycrin 
Norlutate 
Prometrium 
Provera 
------------------------------------------------- 
Question 13: Tea Consumption 
ELIGIBLE: 
-  Subject drinks more than one cup of 
green    
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     tea per week, but is willing to avoid  
    drinking green tea while participating 
in  
    the study (<1 cup per week). 
-   Subject may still consume Black, 
Oolong,  
     white, and herbal teas during study.
CONSENT FORM 
Study Title:  Green tea and reduction of breast cancer risk 
 You are invited to be in a research study of how green tea extract consumption affects 
levels of biological factors (biomarkers) that may influence breast cancer risk. We ask 
that you read this form and ask any questions you may have before agreeing to be in the 
study. This study is being conducted by Mindy Kurzer, Ph.D., Jian-Min Yuan, M.D, Tim 
Emory, M.D., Carolyn Torkelson,M.D. of the University of Minnesota and Karen 
Swenson, Ph.D of Park Nicollet.   
The purpose of this study is to determine the effect of green tea consumption on breast 
cancer biomarkers, such as mammographic density and sex hormone levels, to further 
understand how green tea might reduce the risk for breast cancer.  Although there is 
research that indicates that green tea reduces risk for breast cancer, not much is known 
about how green tea reduces risk. We think that green tea might change the way women 
metabolize estrogen, a sex hormone. We also think that green tea may reduce oxidative 
stress. Both of these physical changes have been shown to reduce breast cancer risk. If 
we can show that green tea changes these factors for the better, it will help us to better 
understand how green tea reduces risk for breast cancer. In addition, we are going to 
evaluate specific genetic variations to find out whether these genetic variations influence 
your physiological responses to the protective effects of green tea on biomarkers of breast 
cancer risk.   
The genetic testing done in this study will measure genetic markers that are not related to 
breast cancer risk or risk of any other disease.  We will simply be examining genetic 
variations that may influence your physiological response to green tea consumption. 
Catechol-O-methyltransferase (COMT) is the main enzyme responsible for breakdown 
and excretion of the active compounds in green tea that we think are responsible for the 
cancer-preventive effects. Previous studies have shown that people with the low-activity 
COMT (which is more common) gene benefit more from possible anti-carcinogenic 
properties of green tea than people with the high-activity COMT gene (which is less 
common). We will also test two other genes that help break down these green tea 
compounds: SULT and UGT genes. You will not receive any results or counseling 
regarding the genetic testing.  No genetic markers related to disease risk will be 
evaluated. 
Procedures: 
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 We anticipate that we will screen up to 8,000 women to find the required 800 participants 
and place them into either the treatment or control group according to a process that will 
not be under your control or the study investigators’.  First, we will perform blood tests to 
confirm that you meet the study criteria and to evaluate your genetic variations in the 
COMT gene.  The results of these tests will determine whether or not you can continue 
with the study.  Once we have determined that you are eligible to continue, the process 
used to place participants into groups will be random (like the flip of a coin). Half the 
participants will be placed in the treatment group and will consume two green tea extract 
capsules twice per day (two in the morning and two in the afternoon) for one year. The 
other half will be placed in the control group and will consume two placebo capsules 
twice per day for one year. Capsule assignments will be made by the University of 
Minnesota Medical Center/Fairview Investigational Drug Services (IDS) Pharmacy.  
Green tea extract and placebo capsules will be identical and will be administered to the 
subjects by a research staff member or nurse at the HNRC blinded to the contents in the 
capsules. Once you are placed into the treatment or control group it will not be possible 
to change groups.  Neither you nor the investigators will know which group you are in.  
Please note that even though you may initially qualify for participation, you may not be 
invited to participate in the study after the first blood tests are performed. 
If you agree to be in this study, we would ask you to do the following things:  
1. Go to the Human Nutrition Research Clinic (HNRC) at the Food Science and 
Nutrition Department of the University of Minnesota in Saint Paul, MN 10 times 
during a 12-month time period. All ten clinic visits will involve a blood draw. At 
five clinic visits, urine samples will also be collected.  Clinic visits 3, 4, 6 and 7 
have the option of being completed at Fairview Crosstown, Fairview Jonathan, 
Fairview Oxboro, Fairview Maple Grove and Fairview Farmington.  The visits 
are described in detail below. 
2. At the beginning of the study and at the 6th and 12th month, collect all urine for 24 
hours in jugs that will be provided.   
3. Go to the University of Minnesota Medical Center (UMMC)/Fairview Breast 
Center, Fairview Southdale Breast Center, or Fairview Maple Grove Breast 
Center for your routine annual mammogram at the end of the study. 
4. Allow a portion of the blood drawn at the first clinical blood draw (about 1 
tablespoon) to be used for DNA analysis. DNA will be isolated from your blood 
sample and stored. We will then analyze the gene variations, which will allow us 
to determine if these gene variations influence your response to green tea extract 
consumption.  
5. Keep your body weight stable during the study, and do not participate in any 
weight loss or weight gain studies or programs.   
6. Consume four capsules per day for one year, containing either green tea extract or 
placebo, as decided by the researchers on a full stomach only, two in the morning 
and two in the afternoon. 
7. Refrain from drinking more than one cup of green tea per week while 
participating in the study. 
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 8. Refrain from drinking more than 7 alcoholic beverages per week while 
participating in the study.  
 
Here is the list of measurements to be made in this study 
• Body weight 
• Height 
• Waist and hip circumferences 
• Blood pressure, heart rate, respiratory rate and body temperature 
• Completing a Food Frequency Questionniare 
• Completing a Health History  Questionnaire 
• Completing a Menopause-Specific Quality of Life questionnaire 
• Blood collections (a little more than 1- 4 tablespoon(s) depending on the clinic 
visit, 14 times) for evaluation of plasma F2-isoprostanes (marker of oxidative 
stress), insulin like growth factor –1 (IGF-1) and its binding proteins (these 
are biomarkers for breast cancer), reproductive hormones, liver enzymes, 
vitamin D, glucose, insulin, HbA1c (a blood test for determining your blood 
glucose over prolonged periods of time), C-peptide (a factor useful in 
assessing insulin function and secretion), HDL-Cholesterol, LDL-C, Total-C, 
TG (lipid factors), oxidized LDL-C (a risk factor for heart disease), hsCRP, 
IL-1β, IL-6, IL-8, TNF-α (proteins in blood involved in immune system 
regulation), prolactin (a hormone that affects growth of the mammary glands), 
adiponectin (a protein that regulates glucose and lipids metabolism), 
osteocalcin, pyridinolines, osteoprotegerin, CTX and NTX (biomarkers for 
bone metabolism), ghrelin and leptin (hormones involved in appetite and 
weight regulation), catechins (green tea bioactive compounds), HBsAg, anti-
HBc, anti-HCV (markers for hepatitis B and C), assessing DNA repair 
capacity and specific changes in the following genes that are related to 
metabolism of the green tea bioactive compounds: COMT, GSTM1, GSTT1, 
UGT, SULT, IGF-1, IGFBP-3, PIK3CB and HSD3B1  
• Urine collection (two spot urines at the clinic in 10% of the subjects and three 
24-hour complete collections for all subjects) for measurement of creatinine (a 
muscle metabolite), estrogens and catechins   
• Mammogram to evaluate the changes in your breast density from baseline 
visit to the end of the study. Breast density changes measured by the 
mammograms will be calculated by aid of a computer program. 
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Detailed Description of Clinic Visits: 
Clinic visit 1  
This clinic visit will take place at the Human Nutrition Research Clinic (HNRC), Food 
Science and Nutrition, University of Minnesota Saint Paul, MN. Measurements taken at 
this visit (hepatitis B and C virus infection, liver function and COMT gene variations) 
will be used to make the final assessment of eligibility. A trained medical professional 
will weigh you, measure your height, take your blood pressure while you are resting and 
then draw 45mL (about 3 tablespoons) of blood. You will be sent home with a urine 
collection container and instructions should you meet all inclusion criteria and return for 
Visit 2 to be randomized into the study.  If you are found to be ineligible due to not 
fulfilling the criteria for inclusion in the study after this visit, you will be notified within 
one month, released from the study and thanked for your time.  This visit will take 
approximately 30 minutes. 
 
Clinic visit 2 
This clinic visit takes place at the HNRC after checking your eligibility at the first clinic 
visit. You should not have had anything to eat or drink other than water for 10 hours prior 
to your clinic visit. A trained medical professional will weigh you, measure your height, 
take your blood pressure while you are resting and will draw 65mL blood (about 4 
tablespoons). After that, your waist and hip circumferences will be measured using a tape 
measure. You will also complete a health survey, a quality of life questionnaire and a 
food frequency questionnaire as part of this visit. At the end of this visit, you will be 
given your first 3 month supply of capsules and a study log for recording pills which you 
have taken. You will also bring the first 24-hour urine collection to the HNRC at this 
visit. This urine was collected the day before and kept refrigerated until delivery to the 
HNRC.  The visit will take approximately 30 minutes. 
 
Clinic visit 3 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 2. A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 4 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 3. A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 5  
This clinic visit takes place approximately one month after clinic visit 4. A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting.  The trained medical professional will draw 5mL of blood 
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 (about one teaspoon), and you will provide a urine sample. You will be asked to bring 
your empty or partially empty bottles of your capsules and study log to this visit. At the 
end of this visit, you will be given your next 3-month supply of capsules and materials to 
complete your 24 hour urine collection for clinic visit 8 in several months. This visit will 
take approximately 30 minutes.  
 
Clinic visit 6 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
approximately one month after your clinic visit 5.  A trained medical professional will 
draw 5mL (about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 7 
This visit will take place at the HNRC or a Fairview clinic mentioned in part 1, page 2, 
within one month after clinic visit 6. A trained medical professional will draw 5mL 
(about one teaspoon) of blood. This visit will take approximately 30 minutes.   
 
Clinic visit 8 
This visit takes place at the HNRC approximately one month after your clinic visit 7. You 
will be asked to not eat or drink anything but water for 10 hours prior to your clinic visit 
and to bring your empty or partially empty bottle of capsules and study log.  A study staff 
member will weigh you and measure your blood pressure, body temperature and heart 
rate while you are resting. A trained medical professional will draw 65mL blood (about 4 
tablespoons). You will also bring your 24-hour urine collection from the previous day. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC. You will be asked to bring your empty or partially empty bottles of your 
capsules and pill diary. As part of this visit, you will complete a quality of life 
questionnaire, and you will be given your next 3 month supply of capsules. This visit will 
take approximately 30 minutes. 
Clinic visit 9 
This visit takes place at the HNRC approximately three months after your clinic visit 8. 
This visit repeats the tests and measurements taken in clinic visit 5. A study staff member 
will weigh you, measure your blood pressure, body temperature and heart rate while you 
are resting. A trained medical professional will draw 5mL of blood (about one teaspoon). 
At this visit, you will also provide a urine sample. You will be asked to bring your empty 
or partially empty bottles of your capsules and study log. At the end of this visit, you will 
be given your last 3 month supply of capsules and materials to complete your 24 hour 
urine collection for clinic visit 10 in several months. This visit will take approximately 30 
minutes.  
 
Clinic visit 10 
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 This is your last clinic visit. This visit will be scheduled at the HNRC approximately 
three months after your clinic visit 9, during month 12 of your participation. You will be 
asked to not eat or drink anything but water for 10 hours prior to this visit and to bring 
your empty or partially empty bottle of capsules, study log and 24-hour urine collection. 
This urine should have been collected the day before and kept refrigerated until delivery 
to the HNRC.  A study staff member will weigh you, measure your blood pressure, body 
temperature and heart rate while you are resting. Your waist and hip circumferences will 
be measured as well. A trained medical professional will draw 65mL of blood (about 4 
tablespoons). You will also complete a quality of life questionnaire and a food frequency 
questionnaire as part of this visit. This visit will take approximately 30 minutes. 
 
Specific procedures to be performed: 
Food Frequency Questionnaire  
At clinic visits 2 and 10 you will complete a questionnaire about your eating habits over 
the past year. This survey is given in a web-based format and should take about 60 
minutes.  
Menopause-Specific Quality of Life Questionnaire 
At clinic visits 2, 8, and 10 you will answer questions regarding your experience of 
certain physical, psychosocial, and sexual symptoms over the previous week. These 
questions are designed to assess your quality of life in association with your menopausal 
experience. The required time to complete this questionnaire will be less than 15 minutes. 
Collection of 24-hour urine samples 
The day before clinic visits 2, 8 and 10, you will collect all urine for a 24-hour period in 
jugs that we provide to you. You will keep them refrigerated and bring them to the clinic 
at the time of your visit. 
 
Mammogram 
As part of your routine medical checkup, you will undergo one mammogram within one 
week of finishing the study.  Also, you might need to wait for your next annual 
mammogram until the Green Tea Study is over, which could be up to 15-16 months from 
your initial mammogram. 
 
Risks of Being in the Study: 
Participating in this study has the following risks: 
First, liver toxicity has been seen in a few subjects who used green tea extract as a weight 
reduction aid. The risk of toxicity from taking manufactured green tea extracts has been 
estimated to be about 1 case out of 83,812 treatments, although no toxicity has been 
reported in any clinical trials performed to date. To be cautious, we will measure liver 
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 enzymes 9 times throughout our study for possible toxicity and tolerance at each visit at 
the HNRC or a Fairview clinic. If your liver enzymes are elevated, you will be informed 
and released from the study. 
 
Second, as with any dietary supplement or pharmaceutical, there is a slight risk of 
stomach upset, nausea, vomiting, and diarrhea.  To prevent any of these digestive 
problems, we advise that you take the study supplement on a full stomach, after breakfast 
and after dinner.  There is also a slight risk of headache from consuming the study 
supplement.  If discomfort persists, you may contact the study coordinators. 
You may experience discomfort from hunger and feel inconvenienced by having stop 
eating 10 hours before the blood draws at visits 2, 8 and 10 of the study.   
Also, there is a small risk of infection and bruising at the needle puncture site when blood 
is taken. The risk is minimal as all needles and equipment are sterilized and the 
procedures are performed by trained phlebotomists: registered nurses and certified 
medical assistants at the HNRC or a Fairview clinic. You may also feel some pain, 
dizziness, or feel faint lasting a few seconds upon insertion of the needle used to draw the 
blood. 
Lastly, screening mammography is the best way to detect early breast cancers.  You are 
currently getting your mammograms approximately every 12 months.  If you participate 
in this study, your mammogram may be delayed by at most 3-4 months.  Some experts 
(U.S. Preventive Services Task Force, 2009) have suggested that this type of delay has 
little effect on the benefits of mammography.  If you wish to have your regular 
mammogram on a yearly basis, we will ask you to have a second limited view research 
mammogram after you have been on the study for 1 year.  The additional limited view 
mammogram would be at no cost to you. 
Benefits of Being in the Study: 
There may be no direct reduction of breast cancer risk as a result of participation in this 
study. Additionally, upon your request we can send the first liver function test results 
conducted at your screening visit to you or your primary care physician. 
Costs:   
No charges will be made for the Human Nutrition Research Clinic (HNRC) any Fairview 
clinic visits while you are a participant in this study. 
Compensation  
You will also receive financial compensation of up to $450 for study participation:  $20 
for completing the first clinic visit, $70 for the next four clinic visits (clinic visits 2, 3, 4 
and 5), $100 for the next three clinic visits (6, 7, 8), $60 for clinic visit 9, and $100 for 
completing the last clinic visit (clinic visit 10). Finally, upon completion of all clinical 
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 research endpoints (visits, questionnaires and mammogram), you will receive another 
$100 at the end of the study.   
Participants found ineligible after completing the first clinic visit will receive $20.00.  
Participants who become ineligible during the study will receive pro-rated compensation. 
Care in the case of injury 
In the event that this research results in an injury, treatment will be available, including 
first aid, emergency treatment, and follow-up care as needed. Care for such injuries will 
be billed in the appropriate manner, to you or your insurance company. If you think that 
you have suffered a research-related injury, let the principal investigator or a study 
coordinator know right away Dr. Mindy Kurzer: (612-624-9789) or study coordinators: 
(612-624-3412). 
 
Your participation in the study may be terminated by the investigator without 
regard to your consent in the following circumstances: 
1. Failure to come to clinic visits after one reschedule 
2. Circumstances change so that you are no longer eligible  
 
Confidentiality: 
The information provided by you and the information taken from the measurements of 
your body will be held strictly confidential and used for the purposes of research only. 
The HNRC, whose staff has completed the federally required training with regard to 
confidentiality of health information in research, will maintain medical records with your 
name on them for the purposes of scheduling and billing procedures only. Any/all 
medical information gathered, test results, lab samples will NOT have your name on 
them. Instead, they will be labeled with a study ID number only. 
Laboratory results and other test results will not be included in the medical record. Your 
name will be associated with your study ID number on one list, to be kept in a locked file 
cabinet.  Your study ID number will appear on all other study records.  Representatives 
of the University of Minnesota or the National Institutes of Health may be given access to 
your records to assure that the study is conducted properly. 
 
All your study records will be kept private, in locked storage according to HIPAA 
standards. None of your information will ever be given to anyone, and your name will 
never be associated with your records on paper or on computer.  In any sort of report we 
might publish, we will not include any information that will make it possible to identify 
you as a subject of this study.  
 
With regard to your blood and urine samples:  
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 • We will send samples of your blood with only a code number on it to the 
University of Southern California (USC) to analyze it for biomarkers of breast 
cancer called IGF-1, binding proteins for IGF-1, as well as reproductive 
hormones. USC will be paid to do these tests .We will NOT tell USC researchers 
your name or give them any identifying information about you. Any excess blood 
will be destroyed when researchers have completed these tests.  
• We will send samples of your blood and urine with a code number on it to 
Rutgers University to analyze it for plasma and urine catechin levels. Rutgers 
University will be paid to do these tests. We will NOT tell Rutgers University 
researchers your name or give them any identifying information about you. Any 
excess blood and urine will be destroyed when researchers have completed with 
these tests.  
• We will store any remaining blood and urine in a freezer in the Food Science and 
Nutrition Building at the University of Minnesota (St. Paul campus). The vials 
will have your study ID on them and the date on which the blood was drawn. 
Your name will NOT be stored with your blood. We will store these vials for up 
to 5 years after the entire study is over. The freezer in which they are stored is 
kept behind a locked door. The only people who have access to this freezer are 
paid research staff members who have completed the federally required training 
with regard to confidentiality of health information in research. The purpose for 
storing these samples is to enable us to conduct additional tests regarding green 
tea health effects. The principal investigator will maintain ownership of these 
samples while they are stored. Samples will be destroyed within five years after 
the completion of the study. You will not receive any results from future tests 
conducted with these stored samples.  
• USC and Rutgers University labs do NOT have access to your name. There is one 
confidential list and file that links your ID to your name. These files will be kept 
in the locked file cabinet as described above. The only people who will have 
access to this list are the principal investigator (Dr. Kurzer) and her research staff, 
who have completed the federally required training with regard to confidentiality 
of health information in research.   
Protected Health Information (PHI) 
Your PHI created or received for the purposes of this study is protected under the federal 
regulation known as the Health Insurance Portability and Accountability Act of 1996 
(HIPAA).  Refer to the accompanying HIPAA authorization for details concerning the 
use of this information.  
A new federal law (2009), called the Genetic Information Nondiscrimination Act (GINA) 
generally makes it illegal for health insurance companies, group health plans, and 
employers of 15 or more persons to discriminate against you based on your genetic 
information. Health insurance companies and group health plans may not request your 
genetic information that we get from this research. This means that they may not use your 
genetic information when making decisions regarding insurability. Be aware that this 
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 new federal law will not protect you against genetic discrimination by companies that 
sell life insurance, disability insurance, or long-term care insurance. 
Voluntary Nature of the Study: 
Your decision whether or not to participate will not affect your current or future relations 
with the University. If you decide to participate, you may withdraw at any time without 
affecting those relationships.  In addition, you may request your blood and urine samples 
to be destroyed following your withdrawal from the study. The procedure to withdraw is 
to call Mindy Kurzer, Ph.D. at (612) 624-9789 or the study coordinators at (612) 624-
3412 and inform them that you wish to withdraw.   
New Information: 
If during the course of this research study, there are significant new findings discovered 
that might influence your willingness to continue, the researchers will inform you of 
those developments. 
 Contacts and Questions: 
The primary researcher conducting this study is Mindy Kurzer, Ph.D.  If you have 
questions, you may contact her at the Department of Food Science and Nutrition, 
University of Minnesota, 1334 Eckles Ave., St. Paul, MN 55108. Phone: (612) 624-9789; 
email: mkurzer@umn.edu. You may also contact the study coordinators in the 
Department of Food Science and Nutrition, University of Minnesota, 1334 Eckles Ave., 
St. Paul, MN 55108. Phone: (612) 624-3412; email: greentea@umn.edu. If you have any 
questions or concerns regarding the study and would like to talk to someone other than 
the researcher(s), you are encouraged to contact the Fairview Research Helpline at 
telephone number (612)672-7692 or toll-free at (866) 508-6961. You may also contact 
this office in writing or in person at University of Minnesota Medical Center/Fairview 
Riverside Campus, 2200 Riverside Avenue, Minneapolis, MN 55454. 
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Statement of Consent: 
I have read the above information. I have asked questions and have received answers. I 
consent to participate in the study. 
 
________________________________________________________________________    
Signature of Participant                                                                                   Date 
 
________________________________________________________________________ 
Name of Participant (printed) 
 
________________________________________________________________________ 
Street Address          City       State      Zip code 
 
________________________________________________________________________    
Signature of Person Obtaining Consent                Date 
 
You will be given a copy of this form for your records. 
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PLEASE NOTE:  
If at any time you have questions or concerns regarding the study, please 
contact any of the GREEN TEA STUDY staff immediately.   
Contact information is included in this handbook and on the website 
(www.greenteastudy.umn.edu).  
 GREEN TEA STUDY staff members are here to assist you throughout the 
study process.  Please do not hesitate to call for any reason (612) 624-3412 
ext. 1 
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 Clinic Visit 1 (screening visit):  
• After receiving your consent at the orientation session, your first clinic visit 
will be scheduled.  
• Measurements taken during this visit will be used to make the final judgment 
of your eligibility.  
• This clinic visit must take place at the Human Nutrition Research Clinic 
(HNRC) located at the University of Minnesota in Saint Paul campus. 
 
What to expect at your Screening Visit: 
Our trained Staff will collect several measurements which include: 
o Weight (in light clothing, no shoes),  
o Height 
o Blood pressure 
o Body temperature  
o Pulse 
o Respiratory rate  
o Draw 2 tubes of blood  
 
• You will be notified within one month if you do or do not qualify for the study. 
 
At this visit you will be given the following materials for your assumed Clinic Visit 2: 
 
o 3-liter urine jug 
o 1-liter travel jug 
o 1-cooler bag  
o 2-collection “hats” 
o 1-small bag of foil-wrapped vitamin 
C  
o 2-Ice-packs for the 24-hr urine 
collection. 
 
o 1-Health History Questionnaire
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 You will need to return the completed Health History Questionnaire and urine jug(s) 
containing your 24-h urine at the clinic visit 2 if you are found eligible for the study.   
 
 
Clinic Visit 2: Will be scheduled after confirming your eligibility after Clinic Visit 1. 
 
 
 
Clinic Visit 2 (baseline visit):  
This clinic visit must be conducted at the HNRC on the St. Paul Campus. 
• Clinic Visit 2 should be scheduled on weekdays between 6:30 am-10:00 am. 
• Do not eat anything or drink anything but water 10 hours before this clinic visit. 
• You must be FASTING for this clinic visit.  
 
What to do to prepare for this visit: 
· DO NOT eat or drink anything (except water) for 10 hours prior to the clinic visit.  
· DO NOT take any medications by mouth during this time.  
· DO NOT drink coffee or tea the morning of your visit. 
· Please bring all months of your study log. 
· Get a good nights’ sleep and drink plenty of water. 
· Be prepared to give about 3 tablespoons of blood.  
· Bring your refrigerated 24-hour urine collection from the previous day.  
 
Measurements at this clinic visit include: 
o Weight (in light clothing, no shoes)  
o Blood pressure 
o Body temperature  
o Pulse 
o Respiratory rate  
o Collection of your 24-hour urine specimen 
 
• Prior to coming to your second visit you will complete the Health History 
Questionnaire that was given to you at your screening visit.  
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 • In addition to your Health History Questionnaire you will need to complete the: 
Dietary History Questionnaire (DHQ) and the Menopause-Specific Quality of Life 
questionnaire (MENQOL). These may be completed at your home or HNRC.  It is 
important to note that completing these questionnaires at the HNRC will extend you 
appointment time up to 2 hours. 
• You will receive your first 3 month supply of the capsules and study log.  Start taking 
supplements the day of this clinic visit. 
• This appointment should take about 30 minutes. 
 
At the end of this clinic visit the study staff will schedule you for your next 
appointment to the St. Paul Campus/ HNRC. 
 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
Clinic Visit 3:  
This visit will take place approximately one month after your last or most recent clinic 
visit. 
This visit may be completed at a partnering Fairview clinic or the HNRC on the St. Paul 
Campus. Please note that at your second visit you had made the decision of which 
location you would prefer to go to for this visit. 
 
What to do to prepare for this visit: 
 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
   
Measurements at this clinic visit include: 
• Blood drawing for assessment of your liver function (1 tube) 
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If you are choosing to use the Fairview Clinics for part of your study visits, please 
schedule your next month’s clinic visit and notify Green Tea Study Staff of this 
time. 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
Clinic Visit 4:  
This visit will take place approximately one month after your last or most recent clinic 
visit. 
This visit may be completed at a partnering Fairview clinic or the HNRC on the St. Paul 
Campus. Please note that at your second visit you had made the decision of which 
location you would prefer to go to for this visit. 
 
What to do to prepare for this visit: 
 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
 
 
Measurements at this clinic visit include: 
• Blood drawing for assessment of your liver function (1 tube) 
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Your next clinic visit is required to be completed at the St. Paul Campus. Several 
days before your next visit you will be contacted by study staff to remind you of this 
appointment. 
Clinic Visit 5:  
This visit will take place approximately one month after your last or most recent clinic 
visit. 
This clinic visit must be conducted at the HNRC on the St. Paul Campus. 
What to do to prepare for this visit: 
• Please bring all months of your study log. 
• The bottles which you have been taken your pills from and any remaining 
capsules. 
• You will need to provide a spot urine sample. 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
Measurements at this clinic visit include: 
• Weight 
• Blood pressure 
• Body temperature  
• Pulse 
• Respiratory rate  
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 • Blood drawing for assessment of your liver function (1 tube) 
 
Study Supplement and Supplies: 
 
• At this visit you will receive 3 new bottles of our study supplement. Please return 
any pills that you may still have along with the bottles they came in. 
• You will receive 24-hour urinary collection materials for your 8th clinic visit. 
o This includes: one 3-liter urine jug, one small bag of foil-wrapped vitamin 
C. Of other supplies are needed please let study staff know and they will 
provide it to you. 
 
At the end of this clinic visit the study staff will schedule you for your next 
appointment that is required to take place at the St. Paul Campus/ HNRC. 
 
You will be responsible for scheduling your next month appointment if not 
coming to St. Paul Campus/ HNRC. 
 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
Clinic Visit 6:  
This visit will take place approximately one month after your last or most recent clinic 
visit. 
This visit may be completed at a partnering Fairview clinic or the HNRC on the St. Paul 
Campus. Please note that at your second visit you had made the decision of which 
location you would prefer to go to for this visit. 
 
What to do to prepare for this visit: 
 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
 
Measurements at this clinic visit include: 
• Blood drawing for assessment of your liver function (1 tube) 
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If you are choosing to use the Fairview Clinics for part of your study visits, please 
schedule your next month’s clinic visit and notify Green Tea Study Staff of this 
time. 
 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
Clinic Visit 7:  
This visit will take place approximately one month after your last or most recent clinic 
visit. 
This visit may be completed at a partnering Fairview clinic or the HNRC on the St. Paul 
Campus. Please note that at your second visit you had made the decision of which 
location you would prefer to go to for this visit. 
 
What to do to prepare for this visit: 
 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
 
Measurements at this clinic visit include: 
• Blood drawing for assessment of your liver function (1 tube) 
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Your next clinic visit is required to be completed at the St. Paul Campus.  
Several days before your next visit you will be contacted by study staff to remind 
you of this appointment. 
Clinic Visit 8: 
This clinic visit must be conducted at the HNRC on the St. Paul Campus. 
• Clinic Visit 8 should be scheduled on weekdays between 6:30 am-10:00 am. 
• Do not eat anything or drink anything but water 10 hours before this clinic visit. 
• You must be FASTING for this clinic visit.  
 
What to do to prepare for this visit: 
· DO NOT eat or drink anything (except water) for 10 hours prior to the clinic visit.  
· DO NOT take any medications by mouth during this time.  
· DO NOT drink coffee or tea the morning of your visit. 
· Please bring all months of your study log. 
· Get a good nights’ sleep and drink plenty of water. 
· Be prepared to give about 3 tablespoons of blood.  
· Bring your refrigerated 24-hour urine collection from the previous day.  
 
Measurements at this clinic visit include: 
o Weight (in light clothing, no shoes)  
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 o Blood pressure 
o Body temperature  
o Pulse 
o Respiratory rate  
o Collection of your 24-hour urine specimen 
 
Study Supplement and Questionnaires: 
 
• At this visit you will receive 3 new bottles of our study supplement. Please return 
any pills that you may still have along with the bottles they came in. 
• You will need to complete an online Menopause-Specific Quality of Life 
questionnaire (MENQOL) prior or the day of your clinic visit.  This questionnaire 
may be completed at home or at the HNRC. 
 
 
At the end of this clinic visit the study staff will schedule you for your next 
appointment to the St. Paul Campus/ HNRC. 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
 
Clinic Visit 9:  
This visit will take place approximately three months after your last or most recent clinic 
visit. 
This clinic visit must be conducted at the HNRC on the St. Paul Campus. 
What to do to prepare for this visit: 
• Please bring all months of your study log. 
• The bottles which you have been taken your pills from and any remaining 
capsules. 
• You will need to provide a spot urine sample. 
• Get a good nights' sleep and drink plenty of fluids. 
• Be prepared to give about 1 teaspoon of blood. 
• You DO NOT need to fast. 
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 Measurements at this clinic visit include: 
• Weight 
• Blood pressure 
• Body temperature  
• Pulse 
• Respiratory rate  
• Blood drawing for assessment of your liver function (1 tube) 
 
Study Supplement and Supplies: 
 
• At this visit you will receive 3 new bottles of our study supplement. Please return 
any pills that you may still have along with the bottles they came in. 
• You will receive 24-hour urinary collection materials for your 8th clinic visit. 
o This includes: one 3-liter urine jug, one small bag of foil-wrapped vitamin 
C. Of other supplies are needed please let study staff know and they will 
provide it to you. 
 
At the end of this clinic visit the study staff will schedule you for your next 
appointment to the St. Paul Campus/ HNRC. 
 
A study staff member will contact you several days prior to your next visit as a 
reminder. 
Clinic Visit 10 (Final visit):  
• Clinic Visit 10 should be scheduled on weekdays between 6:30 am-10:00 am. 
• Do not eat anything or drink anything but water 10 hours before this clinic visit 
• You must be FASTING for this clinic visit.  
 
WHAT TO DO TO PREPARE FOR THIS VISIT: 
· DO NOT eat or drink anything (except water) for 10 hours prior to the clinic visit.  
· DO NOT take any medications by mouth during this time.  
· DO NOT drink coffee or tea the morning of your visit. 
· Get a good nights’ sleep and drink plenty of water. 
· Be prepared to give about 3 tablespoons of blood.  
· Bring your 24-hour urine collection from the previous day.  
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 · Complete the following questionnaires: Menopause-Specific Quality of Life 
Questionnaire (MENQOL) and Dietary History Questionnaire (DHQ) 
 
What to expect at your Final Visit: 
Our trained Staff will collect several measurements which include: 
o Weight (in light clothing, no shoes),  
o Height 
o Blood pressure 
o Body temperature  
o Pulse 
o Respiratory rate  
o Waist and hip circumferences 
 
• You will need to complete your final: Dietary History Questionnaire (DHQ) and the 
Menopause-Specific Quality of Life questionnaire (MENQOL). These may be 
completed at your home or HNRC.  It is important to note that completing these 
questionnaires at the HNRC will extend you appointment time up to 2 hours. 
 
• This appointment should take about 30 minutes. 
 
 
 
 
115 
 
 Summary of Clinical Measurements 
Clinic Visit #:  1 2 3 4 5 6 7 8 9 10 
Measurements           
Weight/vital signs X  X   X   X X X 
Height X                 X 
Measure waist and hip circumferences   X               X 
Sample Collection                   
Blood Draw X X X X X X X X X X 
24 Hour Urine Collection   X      X  X  
Collect Spot Urine     X    X  
Supplement & Questionnaires           
Distribute  Supplement   X      X     X  X  
Collect Bottles & Remaining Supplement         X      X X X  
Health History Questionnaire (HHQ)  X                   
Dietary History Questionnaire (DHQ)   X               X 
Menopause-Specific Quality of Life Questionnaire 
(MENQOL)   X           X   X 
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 Green Tea Study Staff 
Principle Investigator: 
Mindy S. Kurzer, Ph.D. 
Dept. of Food Science and Nutrition- University of Minnesota 
Telephone: (612) 624-9789     
Fax: (612) 625-5272 
Email: mkurzer@umn.edu 
 
 
Study Coordinators: 
 
Jane Mobeck Wilson, RN 
Research nurse 
 
Hamed Samavat 
Ph.D. Nutrition Student 
 
Allison Dostal 
Ph.D. Nutrition & Epidemiology Student 
 
Alyssa Perry 
M.S. Nutrition Student 
 
Sarah Bedell 
Regulatory Support and Coordination 
 
April Rose 
Junior Scientist and Laboratory Coordinator 
 
Study Contact Information 
Address: 1334 Eckels Avenue 
    Saint Paul, MN 55108 
 
Telephone:  612-624-3412 
Fax:   612-626-3037 
E-mail:  greentea@umn.edu
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 Scheduling Questions and Study Concerns: 
 
PLEASE NOTE: If at any time you have questions or problems arise, please 
contact any member of the Green Tea Study staff immediately.  
The Green Tea Study staff members are here to assist you through the study 
process; do not hesitate to call for any reason.  
 
The website may also provide you with study information and details: 
www.greenteastudy.umn.edu. 
 
If leaving a message via telephone or email please provide: 
• Your name and  
• Contact information 
• Brief description about the reason for your contacting the study. 
• If you have a preferred time for us to contact you.  
 
 
If we do not hear from you: 
 
PLEASE NOTE: If a participant does not set up a clinic appointment when it is expected 
to occur, a Green Tea Study staff member will make three (3) attempts to contact the 
participant, at various times, via phone and email, over 7 business days, inquiring of her 
interest in continuing participation and advising of the possibility of termination of her 
study participation. The third message will state that the participant has 72 hours to 
contact Green Tea Study staff to reschedule or to communicate that the participant has 
chosen to end her participation. 
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 HNRC Location, Transportation, and 
Parking 
Human Nutrition Research Clinic (HNRC) 
 
Location  
This building is located on the St. Paul University of Minnesota campus. 
The HNRC is located on the 1st floor of the Food Science and Nutrition Building, Room 
116, 1334 Eckles Ave.  
  
 
 
 
 
 
P  
119 
 
 FREE PARKING AVAILABLE TO STUDY 
PARTICIPANTS 
There are two meters on Commonwealth Ave. between Cleveland Ave. N and Eckles 
Ave. that have been bagged and are reserved for study participants. 
Public Transportation 
Several city bus routes service the St. Paul campus, including 3, 87, and 272.  
Additionally, the U of MN has campus shuttles—routes 121 and 124—that run frequently 
between campuses. Information on specific routes, times, and fares may be obtained by 
calling the Metro transit office at (612)373-3333 or going to their website at 
www.metrotransit.org.  
Directions to HNRC from I-35W 
These directions will take you to the intersection of Eckles Ave and Commonwealth Ave.   
Exit S Cleveland Ave and go south on Cleveland Ave N for about 1.8 miles.  Make a left 
(east) on Commonwealth Ave.  Go one block to Eckles Ave. The HNRC will be ahead 
and to the left; the Dept. of Food Science and Nutrition will be directly to your left. 
Directions to HNRC from I-94 
These directions will take you to the intersection of Eckles Ave and Commonwealth Ave.   
Take exit 236 for MN-180 toward University Ave. Once on MN-180, take the Energy 
Park Drive exit and go right (east) on Energy Park Drive. Take your first left, Raymond 
Ave, and continue onto Cleveland Ave N. Make a right (west) onto Commonwealth Ave. 
Go one block to Eckles Ave. The HNRC will be ahead and to the left; the Dept. of Food 
Science and Nutrition will be directly to your left. 
Parking near HNRC 
Besides the free parking discussed above, you have other options for parking if you 
choose to drive to the HNRC. 
(1) Metered parking is available on Eckles Ave.  
(2) There is a lot directly across from the HNRC for $4.00 (daily). 
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 Fairview Clinics 
• As a Green Tea Study participant, you have the option to complete eight clinic visits 
at one of our partnering Fairview Clinics.   
You may utilize Fairview Service only for clinic visit # 3, 4, 6, and 7. 
• Green Tea Study staff will assist in reminding for these appointments but will not be 
present at the clinic for these visits.  
• In order to have all study documents present for a visit to a Fairview Clinic it is the 
subject’s responsibility to inform the Green Tea Study of the upcoming appointment. 
 When informing the staff of your visit(s) please let them know: What date, 
time and clinic you will be attending for you visit. 
 
Current Participating Fairview Clinics 
• Crosstown Clinic/ Southdale Medical Center 
6545 France Ave, Edina, MN 55435 
Hours: Monday - Friday: 8 AM - 5 PM 
Appointment Line: (952)- 848 - 5600 
 
• Maple Grove Family Medical Center 
14500 99th Ave N, Maple Grove, MN 55369 
Hours:  Monday – Friday 7 AM - 5 PM & Saturday: 8 AM - 5 PM 
Appointment Line: (763) – 898-1000 
 
• Jonathan Clinic 
1447 White Oak Drive, Chaska, MN 55318 
Hours: Monday – Friday 8 AM - 5 PM & Saturday: 8 AM - 12 PM 
Appointment Line: (952) – 448-3500 
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 Current Participating Fairview Clinics - Continued 
 
• Oxboro Clinic 
600 W. 98th St., Bloomington, MN 55420 
Hours: Monday, Wednesday, Thursday & Friday: 8 AM - 5 PM  
Tuesdays: 8 AM - 12 PM 
Appointment Line: (952) – 885-6150 
 
 
• Farmington Clinic 
19685 Pilot Knob Road, Farmington, MN 55024 
Hours: Monday, Wednesday & Thursday: 8 AM – 4:30 PM  
Tuesday: 8 AM – 6:30 PM 
Friday: 8 AM – 4 PM 
Appointment Line: (651) – 463-510
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 Blood Draws 
• During 10 clinic visits, you will have about 1 or up to 12 teaspoons of blood drawn 
each time.   
• The amount of blood drawn is dependent on which clinic visit that you will be 
attending. 
o Visit Numbers: 1,3,4,5,6,7 and 9, Approximately 1 teaspoon of blood will 
be drawn. 
o Visit Number: 2, 8 and 10 - Approximately 12 teaspoons of blood will be 
drawn. These visits are also fasting visits and are preferred to be seen 
between the hours of 6:30-10am Monday-Friday. 
 
What are we drawing your blood for? : 
Blood is drawn to measure the following biomarkers during the aforementioned clinic 
visits: sex hormones (estrogen, estradiol, androstendione hormones), oxidative stress 
biomarkers, green tea catechins, and enzymes related to liver function. 
 
Are there any risks? : 
There is a small risk of infection when blood is taken, but the risk is minimal as all 
needles and equipment are sterilized and the procedures are performed by trained clinical 
staff at the human Nutrition Research Center (HNRC) or a partnering Fairview Clinic.   
You may experience some mild to moderate pain lasting a few seconds upon insertion of 
the needle used to draw the blood.  You may also get a bruise from the blood draw.  
Please inform the clinical staff if you feel faint or nauseous. 
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 24-Hour Urine Collection 
Throughout this Study you will be asked to collect your urine a total of 3 times at home. 
These collections take place at visit 2, 8 & 10. 
Collection supplies: 
To assist you in y our 24 hour urine collection, the study will provide you the following 
supplies: 
• 1-3 Liter plastic jug 
• 1 Liter brown jug 
• 1 Baggie containing 3 grams 
powdered ascorbic acid (Vitamin 
C) 
• 1 thermal/lunch bag  
• Ice packs 
• Urine collection hats 
 
 
 
 
 
 
 
 
 
 
**Upon completion of the study you may 
dispose of all remaining study materials 
at home** 
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 At each of the clinic visits 1, 5, and 9 we will provide you with one large 3-liter 
container and one 1-liter container. If you have these visits at a Fairview Clinic, the 
materials will be delivered to your residence.  These jugs will be used for the collection 
of 24 hours urine during the day before clinic visits 2, 8, and 10.  
You will be provided with one small bag containing foil-wrapped vitamin C. The 
contents of this bag of powdered vitamin C must be put in the large 3-liter jug at the 
beginning of the collection to help preserve the urine. The extra 1-liter collection 
container and accompanying cooler bag with the ice packs are meant to accommodate 
your active lifestyles of work, school, and other commitments.   
You will also be provided with two collection hats. They are designed to make the 
collections easier. You can keep one at work and one at home if you like. Place the hat 
near the front of the toilet bowl before you urinate. After you urinate, pour the urine into 
the container.  Please wipe the hat with a damp paper towel between each use.  
Please follow the instructions below to complete the 24-h urine collection: 
1. On the collection day (the day before your visit), do not collect your first void in the 
morning. That urine was produced in your body overnight and therefore is 
representative of the previous night's urine.  At this point, with the 3 liter jug still 
empty, add the vitamin C powder to the container.  
 
2. Record the time of that first void of the day as your starting time on the label. 
Urine is being produced in your body from that time on and will be collected in 
the day's collection. So although you are not collecting this first void, it is the start 
time for the 24 hours of the collection period.  
 
3. Throughout the day, whenever you are away from home, carry the 1-liter container and 
collection hat with you in the cooler bag with ice packs to ensure a full day’s collection. 
 
4. When you arrive home, immediately transfer the urine to the large 3-liter container 
labeled for that day.  Label your 3-liter urine container with the start and end times as 
well as the appropriate dates. You will be provided with labels to attach to all your 
containers. Keep all containers filled with urine in a refrigerator or cooler with ice. DO 
NOT STORE OUTSIDE DURING WINTER MONTHS.   
 
5. Before coming to the HNRC the next day, void and transfer the last urine into the 3-
liter jug. Note that your start and end time for the 24 hour urine collections will 
depend on what time you get up that first morning. You will need to get up at the 
same time for the days of the 24 hour urine collections.  
 
125 
 
 EXAMPLE: On the day before your clinic visit, you wake up and void at 7:00 a.m., but 
you do not collect since this urine was produced in the previous 24 hours. This is your 
START TIME—7:00 a.m.. On the next day, you wake up again at 7:00 a.m., void and 
transfer the urine into the 3-liter container labeled for the complete 24 hours urine 
collection.  
6.   Keep your 3-liter container of the urine collections in the refrigerator.  
7. You will bring the 3-liter container to the HNRC on your designated clinic visits.  
 
8. You will receive your month 6 and 12 urine collection jugs at the end of clinic visits 5 
and 9 in the HNRC. 
 
What if… 
 If you happen to urinate enough in one day to more than fill the 3-liter container, 
simply use the 1-liter container. Make sure to label both containers and indicate 
there are two containers for that day.  
 
 If you find while collecting urine that you produce more than 3 liters on the first 
day (and this was a normal day for you), please contact the study coordinators 
immediately, and we provide you with additional collection containers for visit 8 
and 10.   
 
 NOTE: Do not fill the container to the top, as it will increase the chance of leaking. 
Instead, once a 3-liter container is ¾ full, begin collecting into the second 3-liter 
container.  Always make sure you have one extra 3-liter container at home if you 
normally produce more than 3 liters urine within 24 hours. 
 
 We do not need to know each time you use the restroom. We are concerned with 
the time frame for the day you collected, which should be 24 hours. 
 
 Make sure you place all labels on the 3-liter jug and extra containers (if any), and 
check on the labels for dates and times, and check the box that says “Vit C added”.  
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 EXAMPLE OF : CORRECT URINE LABEL 
 
 
 
 
 
 
 
Completing Questionnaires 
All participants in the Green Tea Study will be required to complete three (8) 
questionnaires throughout the study.  The questionnaires ask about your health history, 
dietary habits, and menopause symptoms and can be completed either at the clinic or at 
your home. 
HEALTH HISTORY QUESTIONNAIRE (HHQ) 
One health survey will be administered at the screening visit (clinic visit 1) to be turned 
in at clinic visit 2. The survey includes a physical activity interview along with a survey 
asking questions regarding the following: exercise, life events, emotional state, body 
image, menstrual cycle and reproductive history characteristics, and demographics. 
DIETARY HISTORY QUESTIONNAIRE (DHQ) 
You will be completing an online diet history questionnaire (DHQ) at the beginning 
(clinic visit 2) and the end (clinic visit 10) of the study. This survey consists of questions 
about consumption of 144 food items, and it takes approximately 1-2 hours to complete 
it. 
Generally, you can complete this questionnaire either at home or at the HNRC with 
the aid of a research staff member. 
Menopause-Specific Quality Of Life (MENQOL) Questionnaire 
The Menopause-Specific Quality of Life questionnaire assesses the effects of menopausal 
symptoms on health-related quality of life. The collected information from this 
questionnaire will help us to study the possible effects of the supplement on the quality of 
24 Hours Collection               Clinic Visit 2 
Green Tea Study Protocol # 10039 
Study ID # 
VIT C ADDED 
Baseline 
Start Date ____________ End Date_____________ 
  Start time ____:_____ End time _____:______ 
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 your life. This is a self-administered questionnaire including 32 questions, which ask 
about your experience of certain physical, psychosocial, and sexual symptoms over the 
previous week. If you have experienced any of the questioned items, answer “Yes” and 
then rate the experience from zero (not at all bothered) to six (extremely bothered), 
otherwise check the “No” box and proceed to the following item. This questionnaire will 
be online at the beginning, month 6, and the end of study, and can be accomplished in 
less than 15 minutes. 
Taking the Study Supplement 
Instructions for Taking the Green Tea Supplement 
You will be provided the Green Tea supplement or placebo during your visits to the 
HNRC by study staff.    
To remain compliant with our study, please take 2 capsules in the AM hours and 2 
capsules in the PM hours.   
What if: 
• You miss a pill: If it is within the same day as the missed dose, consume the missed 
pill(s) as soon as you remember (with a meal or snack). If the missed pills were on a 
previous day, do not consume the missed dose and record this in your study log. 
 
• You feel nauseous after taking the pills: Try taking the pills with a snack such as 
crackers or toast. If your symptoms don’t improve or get worse, contact the study 
coordinators. 
 
• You lose your pills: Contact the study coordinators ASAP to get the new bottle. 
 
• A child or animal consumes the pills: If it is just one capsule, there should be no 
problem; but if you have no idea about the number of taken pills, or if you think it is 
more than 2, induce vomiting and call the Poison Control Center at: 1-800-222-1222. 
 
• You begin or discontinue a medication while in the study: Let the study 
coordinators know ASAP. 
 
• You leave home for more than one day and you forget your capsules: Call the 
study coordinators ASAP, and record the number of missed pills on your study log.  
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 Example of Study Log: 
 
 
If you need to change your appointment time, you can contact Green Tea Study staff 
at (612) 624-3412 or at greentea@umn.edu. 
If leaving a message, give: 
• Your name 
• Contact information (phone number, etc),  
• Available date and times you are able to come in for your visit. 
o The clinic is open 6:30am-2:30pm Monday-Friday. 
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Thank you for your Participation. 
 
130 
 
